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ABSTRACT 
 
INTERCONVERSION OF THE SPECIFICITIES OF HUMAN LYSOSOMAL 
ENZYMES 
 
SEPTEMBER 2010 
 
IVAN B. TOMASIC, B.S., UNIVERSITY OF MASSACHUSSETS AMHERST 
 
M.S., UNIVERSITY OF MASSACHUSSETS AMHERST 
 
Directed by: Professor Scott C. Garman 
 
 
 
Fabry disease (FD) is an X-linked recessive lysosomal storage disorder (LSD) 
known to affect approximately 1 in every 40,000 males, and a smaller number of females.  
FD results from a deficiency of functional α-galactosidase (α-GAL), which leads to the 
accumulation of terminally α-galactosylated substrates in the lysosome.  The predominant 
treatment is Enzyme Replacement Therapy (ERT), requiring the regular infusion of 
recombinant human α-GAL.  More than half of individuals receiving ERT experience a 
range of adverse infusion reactions, and it has been reported that as many as 88% of 
patients receiving ERT develop neutralizing IgG antibodies against the drug
7
.   
In aim of designing a non-immunogenic treatment candidate for Fabry disease 
ERT, we have engineered the active sites of α-GAL and another homologous family 27 
exoglycosylase named α-N-acetylgalactosaminidase (α-NAGAL) to have interconverted 
substrate specificities.  11 of 13 active site residues are conserved between these two 
enzymes, and we have shown that their substrate specificities can be interconverted by 
mutating the two non-conserved active-site residues.  We report the kinetic properties of 
these two mutants along with wild type controls, and use western blotting to show that 
both mutant enzymes retain their respective wild type enzyme antigenicity.  Structural 
 vi 
 
 
data obtained by X-ray crystallography on the α-GAL mutant (called α-GALSA ) reveals 
the mechanism by which substrate specificity is dictated between these two proteins, and 
provides explanations for the mutant’s reduced catalytic efficiency.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 LSDs  
There are approximately 50 diseases classified as Lysosomal Storage Disorders 
(LSDs), the majority of which are caused by deficiencies in lysosomal enzymes
1
.   
Perhaps one of the best understood LSDs is Fabry Disease (FD), first described 1898.  
FD stems from a patient’s inability to produce sufficient functional quantities of the 
lysosomal enzyme α-Galactosidase A (α-GAL)2.  Human α-GAL is responsible for 
catalyzing the hydrolysis of terminal α-galactose from oligosaccharides, glycoproteins, 
and glycolipids
3.  Individuals lacking functional α-GAL are unable to cleave the terminal 
galactose from (neutral) substrates (most notably globotriasylceramide (Gb-3)), leading 
to their accumulation
3
.   The buildup of Gb-3 in the lysosome directly results in Fabry 
disease (FD) symptoms. 
 Over 400 mutations result in the condition, affecting approximately 1 in every 
40,000 males
3,4
.  Furthermore a number of female heterozygous carriers have been 
identified with symptoms of the X-linked recessive disorder, the manifestation of which 
is believed to be related to skewed X chromosome inactivation.
5
  Common symptoms of 
FD include chronic pain, ocular opacities, skin lesions, liver and kidney impairment, 
vascular deficiencies and or cardiac deficiencies
4
.  Enzyme Replacement Therapy (ERT), 
or repeated intravenous infusion of recombinant α-GAL in the form of either Fabrazyme 
(Genzyme Inc.) or Replagal (Shire), is the only approved treatment
6
.    
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1.2 Problems with ERT 
ERTs, or the infusion of recombinant enzyme for the treatment of LSDs, show 
adverse events including immunogenicity.  Studies conducted on Fabrazyme and 
Replagal have shown that up to 88% of male patients receiving Fabrazyme and 56% of 
male patients receiving Replagal ERT develop IgG antibodies against the drugs
7,8
.  
Additionally 50-55% and 14% of patients receiving Fabrazyme and Replagal respectively 
also experience infusion reactions
9,10
.  A clinical study further reported that out of 60 
patients known to have experienced mild to severe Fabrazyme infusion reactions, 7 
patients (8%) had developed IgE antibodies
9
. 
IgG antibody formation against Fabrazyme and Replagal is serious as it has been 
shown to have substantial neutralizing effects on α-GAL activity (as high as 74% in 
vitro)
11
.  This could possibly lead to a loss of drug efficacy over time
11,12
, consequently 
requiring an increase in dosage to overcome IgG antibody neutralization
11,12
.  This may 
explain why Fabrazyme appears more efficacious than Replagal at its recommended 
dosage of 1.0mg/kg
9
 (vs. Replagal 0.2 mg/kg
10
).  However many of the symptoms 
commonly associated with Fabrazyme or Replagal ERT infusion reactions (chills, fever, 
acroparesthesias, dyspnea, etc.
9,12
) are also believed to result from the presence of these 
IgG antibodies
12
.  Hence higher dosage requirements include the possibility of more 
severe infusion reactions, and equate to higher production costs.  Furthermore over 1% of 
Fabrazyme ERT patients experience severe anaphylactic reactions
9
.   Not surprisingly, 
most patients are administered anti-inflammatory drugs (e.g. acetaminophen) as pre-
treatments to Fabrazyme infusion, and in some cases anti-histamines or steroids are also 
pre-administered when patients demonstrate a history of reactions
9,11
.   
  
3 
 
Clinical studies indicate that Fabrazyme has a higher instance of causing IgG 
antibody formation as compared to Replagal
9,10,11
, raising the question of whether the 
different glycosylation states or the different dosages are responsible for this  
phenomenon
11
.  After market studies on the two drugs examining IgG antibody formation 
reported no statistical difference in the number of patients who developed IgG antibodies 
against either drug when the administered dosages were equal
11
.  As the two recombinant 
polypeptide sequences are identical
13
, these data suggest that the polypeptides (not their  
glycosylation) are responsible for IgG antibody formation.  Further in support of this 
hypothesis, neutralizing IgG antibodies formed against Fabrazyme have proven to be 
equally as neutralizing against Replagal in vitro
12
.  This leads us to ask why patient 
immune systems would react to an essentially WT α-GAL polypeptide, normally present 
in all healthy individuals, as foreign antigen after infusion.   
One possible explanation centers on FD being a protein folding disorder
4
.  Recent 
evidence implicates many FD causing mutations as potentially recognized by cellular 
quality control systems such as ERAD
14
 (Endoplasmic Reticulum Associated 
Degradation), resulting in protein degradation and failed lysosomal trafficking.  This 
explains why most male FD patients express almost no α-GAL12.  Consequently these 
patients may never have established α-GAL self-tolerence12 during innate immune 
system self/non-self differentiation.  This hypothesis also explains why the majority of 
female FD patients do not develop IgG antibodies to α-GAL infusion9, 11, 12, as almost all 
female FD patients are heterozygous for the X-linked recessive disorder
9, 11,12
.  Hence 
these female patients likely retain α-GAL self-tolerance as they express at least some α-
GAL due to their dominant GLA allele on their second X-chromasome.   
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1.3  α-N-Acetyl-Galactosaminidase 
Structurally and catalytically similar to α-GAL, α-N-Acetylgalactosaminidase (α-
NAGAL) is also a human lysosomal enzyme, and is responsible for the catalytic cleavage 
of terminal α-linked N-acetyl-galactosaminides from glycosylated substrates15,16.  
Deficiency of functional α-NAGAL results in the accumulation of glycosphingolipids 
and sialylated substrates, leading to the autosomal recessive disorder known as Schindler 
disease
16
 (SD).  Symptoms of SD include infantile neurodegeneration (group 1), adult 
onset mild retardation (group 2, also known as Kanzaki disease), or symptoms ranging 
from seizures to autistic behavior (group 3)
15,16
.  Currently, no treatment for Schindler 
disease exists.  Furthermore as SD symptoms are primarily neurological
15
, it is unlikely 
ERT would prove successful in treating the disease, as any replacement enzyme must 
cross the blood brain barrier
17
.   
 
1.4 Solution to ERT Immune-Response Problems 
The known immunogenicity problems associated with ERT for Fabry disease lead 
us to propose a novel approach.  We hypothesize engineering a protein that patients 
already make, but with a new enzymatic activity.  To the immune system this enzyme 
would appear as self, preventing immune response, but at the same time replace the 
missing enzyme's activity.   
We have rationally engineered the active sites of two human enzymes α-GAL and 
α-NAGAL to have interconverted substrate specificities.  Human α-GAL is normally 
responsible for the hydrolysis of terminal α-Galactoside3,18, while human α-NAGAL is 
predominantly responsible for the hydrolysis of terminal α-GalNAc containing 
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substrates
16.  Both human α-GAL and α-NAGAL are normally found in the lysosome as 
homodimeric glycoproteins, and share 46% amino acid sequence identity
3,16 
(figure 1).  
Crystal structures of human α-GAL and α-NAGAL solved in 20043 and 200916 
respectively show that both proteins contain an N-terminal (β/α)8 barrel (which contains 
the 13 active-site residues), and a C-terminal β sandwich domain comprised of eight 
antiparallel β strands3,16.  The N-terminal domains correspond to the catalytic domain, 
while the C-terminal domains have no known function
3,16
.  Comparing the active sites of 
α-GAL and α-NAGAL shows that 11 of the 13 active site residues are conserved between 
the two enzymes (see appendix for active site residues).  The different substrate 
specificities of the two enzymes are solely dictated by the two non-conserved active-site 
residues, E203/L206 (α-GAL), and S188/A191 (α-NAGAL).   
 Using site-directed PCR mutagenesis, we have engineered point mutations into 
GLA (α-GAL) and NAGA (α-NAGAL) generating two double mutants we call α-GALSA 
and α-NAGALEL respectively.  In order to interconvert the substrate specificities of these 
two enzymes we have mutated α-GAL active-site residues Glu 203 to Ser and Leu 206 to 
Ala (E203S/L206A), and α-NAGAL active-site residues Ser 188 to Glu and Ala 191 to 
Leu (S188E/A191L).  We hypothesized that these mutations should generate an α-
NAGAL enzyme with α-GAL activity/substrate specificity (α-NAGALEL ), and an α-
GAL enzyme with α-NAGAL activity/substrate specificity (α-GALSA ).   
In this thesis, we show that these mutants maintain their respective WT immuno-
reactive properties.   Kinetic studies performed on both mutants and WT enzyme controls 
show that substrate specificities and activity were interconverted between the mutants.  
The data indicate that α-NAGALEL shares kinetic properties similar to WT α-GAL, and 
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that α-GALSA exhibits kinetic properties of an α-NAGAL enzyme. Western blots 
performed on both double mutants and WT enzymes with anti α-GAL and anti α-
NAGAL IgG polyclonal antibodies show that both mutants maintain their respective WT 
parent enzyme's antigenicity.   
We also determined four crystal structures of the α-GALSA mutant with either α-
galactose, α-GalNAc, or the cryoprotectant glycerol (two structures) soaked into the 
active site. The crystal structures reveal the structure-activity relationship dictating 
substrate specificity between α-GAL and α-NAGAL.  The crystallographic data also 
provide insight into why α-GALSA is less catalytically efficient than WT α-NAGAL.  The 
data show that α-NAGALEL could be a viable alternative ERT for Fabry disease that 
could potentially avoid common immune-response issues associated with enzyme 
replacement therapy.  [Michaelis-Menten kinetic studies and western blot data were 
obtained in collaboration with Matt Metcalf (University of Massachusetts Amherst) on 
the α-NAGALEL mutant (cloned, expressed, and purified by Matt Metcalf).  Abby Guce 
and Nat Clark (University of Massachusetts Amherst) also participated in this project, 
cloning and expressing WT α-GAL and α-NAGAL respectively.] 
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CHAPTER 2 
RESULTS 
 
2.1 PCR Mutagenesis 
 Point mutations were introduced into GLA and NAGA via PCR mutagenesis 
(Methods).  The PCR mutagenesis strategy uses mismatches designed into the forward 
PCR primer to introduce point mutations into the gene of interest.  The majority of the 
DNA amplified during PCR mutagenesis contained the desired point mutations.  
Successful PCR mutagenesis was analyzed via agarose gel electrophoresis stained with 
EtBr (figure 2).  Restriction digest controls of uncut super-coiled plasmid and single-
digest linear plasmid were subjected to agarose gel electrophoresis alongside the 
mutagenesis products.  Figure 2 illustrates that PCR amplification of pIB-V5-His-TOPO-
α-GAL-1& 4 (parallel experiments) occurred, using primers designed with the desired 
mismatched bases.  The starting concentration of plasmid for each reaction was 0.2 pg/µL 
and is not visible on an agarose gel.  The PCR products running at 4.8 kb match the size 
of control plasmid linearized via single restriction enzyme digestion (lane 11, lane 3 
single-digest control did not appear for unknown reasons).   The data indicate that the 
PCR mutagenesis reactions yielded products of the appropriate size expected for 
linearized pIB/V5-His-TOPO-α-GALSA.  Mutagenesis products from lanes 6 and 12 
demonstrate the strongest amplification, and were chosen for ligation and transformation. 
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2.2 Ligation and Transformation 
PCR products from lanes 6 and 12 were ligated with T4 DNA Ligase, and used to 
transform both TAM-1 and NEB E. coli cells in tandem experiments (on ampicillin 
plates). Isolated DNA was subjected to restriction enzyme digestion to assay for plasmid 
integrity.  Each isolated plasmid was subjected to a single (HinDIII) and double (HinDIII 
+ XhoI) digestion.  If intact, the single-digest reaction should linearize the 4.8 kb plasmid 
DNA, while the double-digestion should cut around the 1.2 kb α-GAL GLA insert.  
Restriction enzyme digestion was analyzed via agarose gel electrophoresis.  The agarose 
gel (figure 3) shows that all 6 digested α-GALSA mutant candidates contain the 1.2 kb 
GLA insert, indicating that all 6 isolated plasmids are intact. 
 
2.3 DNA Sequencing 
Sequencing data on the 6 isolated plasmids show that 1 of the 6 plasmids 
contained the desired point mutations.  Part of the sequence chromatogram highlighting 
the desired codon mutations (GAG → TCG (E203S) and CTT → GCT (L206A)) is 
shown in figure 4, aligned to the WT GLA sequence. 
 
2.4 Stable Cell Line 
After DNA sequencing data verified the presence of the α-GALSA mutations, 
Invitrogen High-5 (Tn5) and Sf21 insect cells were transfected with the α-GALSA 
construct (figure 5).  Stable cell lines were generated via antibiotic selection with 
blasticidin (figure 6).  The α-GALSA construct contains a blasticidin resistance gene, and 
cells that integrate the vector into their genomes should become blasticidin resistant.   
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Protein expression was analyzed using western blots (figure 7).  Two western 
blots were performed, one probing with polyclonal anti-α-GAL, and the other with 
polyclonal anti-hexahistidine antibodies.  Both western blots show that α-GALSA 
expressed in High-5 insect cells.  Coomassie stained protein appears between the 56 kDa 
and 43 kDa MW markers, matching the 50 kDa predicted size for glycosylated α-GAL 
subjected to SDS-PAGE.  Sf21 insect cells did not express any detectable protein.  Sf21 
cells are more commonly used for baculovirus amplification, rather than protein 
expression
19
. 
 
2.5 Large-scale Expression and Purification 
An overview of the α-GALSA purification process is presented in figure 8.  Large-
scale suspension cultures of the α-GALSA stable-cell line were grown to a density of 5-6 
x 10
6
 cells/ml.  α-GALSA contains a secretion signal and is secreted into the media.  8 
liter cultures were subjected to centrifugation to pellet the cells, and the supernatant was 
collected.  Collected supernatant was concentrated and buffer exchanged using a 
prep/scale tangential flow Millipore cartridge (MW cutoff of 10 kDa).  This was done to 
remove contaminant commonly present in SFX media that removes Ni from Ni-
Sepharose resin.  The supernatant was concentrated by tangential flow filtration to a 
volume of 1 liter for chromatography (figure 9).     
 
2.6 Ni Affinity Chromatography 1 
A liter of concentrated retentate was loaded onto a prepacked 5 ml Ni-column at a 
flow rate of 2 ml/min using a Bio-Rad Biologic Duo-Flow FPLC (Methods).  A 25 ml 
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wash step (Ni-Wash Buffer) preceded a very shallow linear elution gradient of 0 to % 
Ni-Elution Buffer over a volume of 300 ml. Fractions were collected every 2 ml.  The 
UV 280 nm absorbance chromatogram (generated during chromatography) shows a broad 
peak between an elution volume of ~120-240 ml (fractions 60-120) (figure 10).  This 
broad peak is preceded by a larger peak between an elution volume of 50-100 ml 
(fractions 23 – 55), representing a common large molecular weight contaminant.    
α-GALSA fractions were monitored using SDS-PAGE (figure 10).  The SDS gel 
shows the majority of pure α-GALSA eluting between fractions 80-137.  Pure α-GALSA 
fractions were pooled and concentrated.  Pure α-GALSA was stored in 10 mM NaH2PO4 at 
pH 6.5.  The SDS gel shows that fractions 53-79 also contain α-GALSA protein, but that 
these fractions contain contaminants that eluted with the protein of interest.  Hence, these 
fractions were pooled separately and subjected to an additional Ni affinity purification, 
along with the supernatant flow-through from this first Ni-purification. 
 
 
2.7 Ni Purification 2 
An identical protocol to the one used for the first Ni affinity purification was used 
for the second, and fractions were similarly monitored via SDS-PAGE.  The 280 nm 
absorbance chromatogram and the corresponding SDS gel are shown in figure 11.  A 
large molecular weight contaminant eluted between fractions ~25-60.  The SDS gel 
shows that pure α-GALSA eluted between fractions 70 and 118.  The area corresponding 
to these fractions is circled in blue in figure 11.  Pure α-GALSA was pooled and 
concentrated, and stored in 10 mM NaH2PO4 at pH 6.5.  α-GAL
SA
 protein from the first 
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Ni affinity purification was pooled with pure protein from the second and further 
concentrated to 6.21 mg/ml.  Remaining impure α-GALSA fractions (fractions 56-69) 
were further purified using anion exchange chromatography.  
 
2.8 Anion Exchange Chromatography 
See methods for the anion exchange chromatography protocol.  Eluted fractions 
were monitored via SDS-PAGE and UV 280 nm absorbance (figure 12).  The SDS gel 
indicates that pure protein matching the predicted size of α-GALSA appears between the 
56 kDa and 43 kDa markers (fractions 60-137).  Fractions 70-137 were pooled, 
concentrated, and stored in 10 mM NaH2PO4 at pH 6.5.  Pure α-GAL
SA
 from the two Ni 
affinity chromatography purifications and the single anion exchange chromatography 
purification was pooled, and further concentrated to a concentration of ~7 mg/ml.  
 
2.9   Immunogenicity 
Figure 13 depicts the four enzymes (α-GAL, α-GALSA, α-NAGAL, α-NAGALEL) 
analyzed with SDS-PAGE, and stained with Coomassie Brilliant Blue.  The SDS gel 
shows that α-GAL and α-GALSA both run at about 50 kDa in lanes 1 and 2 respectively, 
and that both α-NAGAL and α-NAGALEL run at about 52 kDa in lanes 3 and 4 
respectively.  This result is as expected, as each mutant is only two amino acid residues 
dissimilar from its respective WT enzyme, and accordingly should not display a large 
difference in mass.  Additionally all bands on the SDS gel appear equally intense, 
showing the four enzymes are at approximately equal concentrations.   
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α-GAL 
Western blots of α-GAL and α-NAGAL along with their respective mutants, 
probing with IgG polyclonal anti-α-GAL and polyclonal anti α-NAGAL antibodies, are 
shown in figure 13.  Only α-GAL and α-GALSA react with IgG anti α-GAL antibodies, 
and only α-NAGAL and α-NAGALEL react with IgG anti α-NAGAL antibodies.  These 
data show that α-GALSA and α-NAGALEL maintain their respective WT enzyme’s 
antibody epitopes, and show that the mutants and their respective WT enzymes do not 
cross-react with each other’s antibodies. 
 
2.10 pNP Activity Assays 
To measure enzyme activity, kinetics, and substrate specificity, the enzymatic 
hydrolysis of the synthetic substrates pNP-α-Gal or pNP-α-GalNAc was monitored at an 
absorbance wavelength of 400nm at 37°C.   The pNP assays function as shown below, 
(for detailed protocol see appendix A): 
 
pNP-α-Gal + H2O                                 α-D-Galactose + para-Nitrophenolate  
pNP-α-GalNAc + H2O                                 α-GalNAc + para-Nitrophenolate  
 
2.11 Optimal pH and Buffer Conditions 
Optimal pH and buffer conditions for α-GALSA activity were experimentally 
determined by measuring specific enzyme activity at varying pH conditions, in either 
citrate or phosphate buffer.  The plot of α-GALSA activity vs. pH (from pH 3 to 9.8) in 
either citrate or phosphate buffer shows that α-GALSA activity was optimal at pH 4.5, in 
citrate buffer (figure 14).  Similar activity assays were performed (by Abby Guce and 
α-NAGAL 
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Matt Metcalf) on α-GAL, Fabrazyme, α-NAGAL, and α-NAGALEL (data not shown), 
also indicating that pH 4.5 and citrate buffer show the optimal activity of these enzymes.  
pH 4.5 is representative of lysosomal pH
20
. 
 
2.12 Specific Activity  
Enzyme activity and substrate specificity of Fabrazyme (recombinant human α-
GAL from CHO cells, Genzyme Inc.), α-GALSA, and human α-NAGAL (produced in 
insect cells) was measured.  The assay involves incubating the enzyme of interest with 
synthetic substrate for 10 min, then quenching the reaction with borate buffer (pH 9.8).  
The amount of para-nitrophenol hydrolyzed from synthetic substrate by each enzyme is 
then measured by absorbance wavelength of 400nm.   Absorbance measurements were 
used to calculate the amount of normalized activity using Equation 1 (appendix). 
The results (figure 15) show that the catalytic activity of α-GALSA resembles that 
of α-NAGAL more closely than that of α-GAL.  α-GALSA and α-NAGAL both 
demonstrate an affinity for hydrolyzing pNP-α-GalNAc that is about 7 times greater than 
their affinity to hydrolyze pNP-α-Gal.  The data indicate that α-GALSA is about 3 times 
less active than WT α-NAGAL.  To more thoroughly understand the catalytic properties 
of α-GALSA, Michaelis-Menten kinetic measurements on α-GALSA, α-NAGALEL, and 
WT enzyme controls were performed. 
 
2.13 Michaelis-Menten Kinetics 
Michaelis-Menten kinetic data on the four enzymes (α-GAL, α-GALSA, α-
NAGAL, and α-NAGALEL) were measured to quantify changes in substrate specificity 
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(kcat/Km) and catalytic efficiency (kcat) relative to WT enzyme controls.  To obtain kinetics 
data on these enzymes, the amount of para-nitrophenol hydrolyzed from synthetic 
substrates pNP-α-Gal or pNP-α-GalNAc was measured with respect to time, at different 
substrate concentrations (methods).  The data (figure 16) indicate that both α-GALSA and 
α-NAGALEL exhibit interconverted substrate specificities that more closely reflect 
specificities resembling that of WT α-NAGAL, and α-GAL respectively.   
α-GALSA: α-GALSA specificity for α-GalNAc is about 40 times greater than its 
specificity for α-Gal, its natural substrate.   The results show that α-GALSA exhibits a kcat 
of about 21.5 sec
-1
 against pNP-α-GalNAc, while α-NAGAL exhibits a kcat of about 15.1 
sec
-1 against the same substrate.   This shows that α-GALSA is as efficient as α-NAGAL at 
catalyzing the hydrolysis of pNP-α-GalNAc once substrate has reached the active site.   
However, the Km of α-GAL
SA 
(21.0 mM)
 
is markedly higher than that of WT α-NAGAL 
(Km=0.68 mM) against the same pNP-α-GalNAc substrate.  Hence, the specificity 
constant (kcat/Km) of α- GAL
SA 
against pNP-α-GalNAc is about 20 fold lower than that of 
α-NAGAL, being ~1.03 (mM-1 sec-1) vs. 22.4 (mM-1 sec-1) respectively.   
α-NAGALEL: The NAGA mutations have completely eliminated any of the 
mutant’s native α-NAGAL activity, as attempts to measure kinetics against pNP-α-
GalNAc yield measurements indistinguishable from blank readings.  This result is 
comparable to α-GAL, which also shows no activity toward pNP-α-GalNAc.  The Km of 
α-NAGALEL against pNP-α-Gal is close to that of α-GAL, being 7.6 mM and 6.9 mM 
respectively.  The data show that α-NAGALEL catalyzes the hydrolysis of pNP-α-Gal 
with a catalytic efficiency (kcat) of 13.7 sec
-1
, which is less than three times lower than the 
kcat α-GAL displays against pNP-α-Gal, which is 37.8 sec
-1
.  Accordingly, the specificity 
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constant (kcat/Km) of α-NAGAL
EL
 against pNP-α-Gal is only about three times lower than 
that of α-GAL, being 1.8 (mM-1 sec-1) and 5.5 (mM-1 sec-1) respectively.  Hence, the data 
show that the NAGA mutations converted the substrate specificity of α-NAGAL to more 
closely reflect the substrate specificity of human α-GAL.    
 
2.14 X-Ray Crystallography 
Four α-GALSA crystal structures were determined with either α-galactose, α-
GalNAc, or glycerol bound to the enzyme active site.   The structures allow us to better 
understand the nature of how the GLA mutations alter substrate specificity of the enzyme.  
Crystallization screens were set up based on previous α-GAL crystallization conditions, 
using the hanging drop vapor diffusion method.   
Conditions yielding crystals contained a reservoir solution of 8% or 12% 
polyethylene glycol (PEG) 8000, 22 mM Mg(OAc)2, and 100 mM Sodium Cacodylate 
pH 6.5.  Photographs of crystals obtained with these reservoir solutions are shown in 
figure 17.  Crystals obtained with a reservoir solution of 12% PEG 8K, etc., initially 
yielded 500 μm crystals showing only two-dimensional growth with fraying (figure 17 
D).  These crystals were not suitable for data collection.  However, a few crystals of 
acceptable quality (figure 17, E) were later obtained from this reservoir solution when 
macroseeding techniques were employed, and used for data collection.  Overall, of the 24 
conditions initially screened, two conditions yielded diffraction quality crystals. 
Crystals were harvested stepwise from their reservoir solutions, and ligand-soaked 
(with α-Gal or α-GalNAc), before being transferred into a 20% glycerol based 
cryoprotectant.  Crystals were flash cooled with liquid nitrogen, and then transferred to a 
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gaseous stream of liquid nitrogen at 100˚ K for X-ray diffraction screening.  Screening 
was done in-house using a Rigaku MSC RUH3R X-ray generator, and diffraction images 
were digitally detected using Raxis IV++ detector.  The crystal from figure 17 (B) was 
subjected to an exposure time of 5 min.   The diffraction image shows that the crystal 
lattice is consistent with that of protein, exhibits non-overlapping spot shape, and has a 
low mosaicity.   Diffraction data was collected at the Brookhaven National Laboratory’s 
X6A beamline, and at Argonne National Laboratory’s NECAT 24-ID-C beamline.  A 
collection image is shown in figure 18 (B), taken with an exposure time of 30 seconds at 
BNL X6A beamline.   
Crystallographic data (table 1) show that crystals obtained from a reservoir 
solution of 8% or 12% PEG 8K etc., grew with P212121 or C2221 space group symmetry, 
respectively.  Diffraction images were processed using HKL2000
21
 and phased by 
molecular replacement in AMoRe
24
, or by Fourier synthesis with human α-GAL mutant 
D170A (PDB: 3HG3)
21
. Atomic models were built using the program O
25
, and refined 
with REFMAC5
24
. Ramachandran plots were computed using PROCHECK
26
, and 
coordinates were superimposed using LSQMAN
27
.  The four structures show a range in 
resolution from 2.1-3.1 Å, with the α-GalNAc bound structure exhibiting the best 
resolution at about 2.1 Å, and the best Rwork/Rfree at 17.62/21.82.   Ramachandran plots of 
the four structures show ~90% of the residues fall in the favored region.   
Superimposition of α-GALSA and α-NAGAL by 290 Cα atoms in their (β/α)8 
barrels shows an RMS deviation of 0.58 Å (figure 19).  The α-GalNAc ligands 
superimpose almost exactly, with the 15 atoms in the GalNAc ligands having an RMS 
deviation of 0.38 Å.  This is quite remarkable, as only 46% of the residues are conserved 
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between the two enzymes.  Superimposition of galactose bound α-GALSA with WT α-
GAL reveals the active sites are similar, but that the two structures demonstrate variation 
in their active sites beyond the E203S/L206A substitutions.  The data show that the D170 
catalytic nucleophile moves, occupying the space vacated by the E203S substitution.   
This is likely responsible for the diminished catalytic efficiency exhibited by α-GALSA, 
as D170 participates in important hydrogen bonding contacts with active site residues 
Y134 and Y207.    
Two separate crystal structures of α-GALSA were determined with the glycerol 
cryoprotectant soaked into the active site. Each one of the two crystals (having P212121 or 
C2221 space group symmetry) contained two monomers of α-GAL
SA
 per asymmetric 
unit.  This allowed us to compare four crystallographically independent glycerol-bound 
active sites (figure 19), which showed that one of the four monomers was unique.  
Significant differences included the glycerol cryoprotectant binding in an alternate 
orientation, an alternate R227 side chain rotamer position, and the movement of the β6-
α6 loop harboring residue D231, the catalytic acid-base.  This novel reorganization of the 
active site in two of the four α-GALSA structures indicates that the E203S/L206A 
substitutions have reduced the structural integrity of the enzyme, likely lowering its 
stability and contributing to the low catalytic efficiency of this mutant.   
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CHAPTER 3 
DISCUSSION 
 
88% of patients receiving recombinant α-GAL enzyme replacement therapy for 
Fabry disease develop IgG antibodies against the drug.  Since Fabry disease is an X-
linked recessive disorder, male Fabry patients only harbor a single defective copy of 
GLA.   In most male patients this results in failed trafficking of α-GAL to the lysosome4.  
It is believed that most male FD patients develop IgG antibodies towards α-GAL because 
they have never become immunologically self-tolerized to the enzyme.  In line with this 
hypothesis, heterozygous female FD patients do not mount IgG responses toward the 
enzyme
9,11,12
.  Hence, Fabry patients would experience a greater clinical benefit if a non-
immunogenic enzyme replacement therapy for FD were developed.   
Western blots probing with anti α-GAL and α-NAGAL antibodies show that α-
GAL and α-GALSA only react with anti α-GAL antibodies, while α-NAGAL and α-
NAGAL
EL
 only react with anti α-NAGAL antibodies.  Although α-GAL and α-NAGAL 
exhibit similar folds and share 46% sequence identity, the sequences show enough 
variation to prevent cross-reactivity between the two proteins.  Hence, we have shown 
that α-NAGALEL exhibits substrate specificity similar to that of α-GAL, yet maintains its 
α-NAGAL parent enzyme antigenicity.  Although less catalytically efficient than α-GAL, 
α-NAGALEL could provide a potential efficacy gain over either Fabrazyme or Replagal if 
the reduced immunogenicity of the mutant eclipses its approximate three fold reduction 
in activity compared to WT α-GAL.  In line with this hypothesis, Sakuraba and 
colleagues generated a protein similar in design to α-NAGALEL (except expressed in 
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CHO cells)
22
.  They showed that administering α-NAGALEL to a mouse model of FD 
effectively reduced Gb-3 levels in the lysosome when compared to control mice
22
.   
Likewise, the substitutions in α-GALSA generated an enzyme with specificity for 
the α-GalNAc substrate, while retaining the mutant’s WT enzyme immunogenicity.  The 
crystal structures show that by converting the larger residues E203 and L206 to S and A 
respectively, the active site of the enzyme was enlarged enough to accommodate the 
bulkier N-acetyl group at the 2-position of the α-GalNAc sugar ring.  This N-acetyl group 
at the 2-position on the sugar ring is normally occluded from the active site of WT α-
GAL by steric clashes, allowing α-GAL and α-NAGAL to discriminate between their 
substrates.   
The crystal structures of α-GALSA indicate that the mutant has a more dynamic 
and flexible active site than WT α-NAGAL.  Although enlarging the α-GALSA active site 
via the shortening of residues E203 and L206 in the β5-α5 loop did facilitate the 
accommodation of the bulkier α-GalNAc substrate, it simultaneously removed some 
packing interactions provided by these residues.  The R227 side chain moves into the 
space previously occupied by the side chain of E203, and the β6-α6 loop (D231) move 
into the space previously occupied by the side chain of L206 in the glycerol bound 
structure.  A more dynamic active site is further supported by the higher atomic B-factors 
in the β6-α6 loop in the glycerol-soaked structure, indicating higher active site mobility.   
It is perplexing that α-GALSA and α-NAGAL are not more catalytically 
comparable given that they share a near identical active site constellation.   However α-
NAGAL likely provides additional steric support to its active site via residues Y215 and 
F232, which participate in van der Waals interactions stabilizing the β6-α6 loop (which 
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moves in the α-GALSA structure).  α-GALSA lacks this additional stability, as its 
equivalent residues F229 and T246 do not interact.  Hence it is possible that the catalytic 
efficiency of α-GALSA could be improved by making an α-GALSA mutant with Y and F 
residues substituted for F229 and T246, respectively.  This mutant's active site may prove 
to be less dynamic, yet still be able to accommodate α-GalNAc, increasing its catalytic 
efficiency.   
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CHAPTER 4 
SUMMARY 
 
We have successfully engineered the E203S/L206A amino acid substitutions into 
the α-GAL protein via PCR mutagenesis, and expressed and purified the α-GALSA 
mutant from insect cells.  We have shown that α-GALSA exhibits kinetic properties 
resembling that of WT α-NAGAL more so than that of WT α-GAL.  We have shown that 
the α-NAGALEL mutant exhibits kinetic properties close to that of α-GAL, and has 
completely lost the ability to catalyze the hydrolysis of pNP-α-GalNAc.  Both α-GALSA 
and α-NAGALEL retain their respective WT enzyme antigenic properties, and more 
importantly we have demonstrated that the mutants do not cross react with each other’s 
antibodies.   The crystallographic data reveal the mechanism by which substrate 
specificity is interconverted between these two enzymes, and provides insight into why 
the mutants exhibit reduced catalytic efficiency compared to WT enzymes.  α-NAGALEL 
may prove fruitful as an alternative enzyme replacement therapy for Fabry disease in 
patients where adverse immune reactions to the current treatment is an issue. 
  Rational protein design has always been a difficult process.  For example, the 
conversion of trypsin to chymotrypsin activity requires 11 residue substitutions
23
.  Here 
we have shown and reaffirmed that a rational design approach can be successfully used to 
design proteins with new enzymatic function.  This technique may prove to be a useful 
approach in designing new enzyme replacement therapies as treatments for a variety of 
diseases where immune response may be an issue.    
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CHAPTER 5 
METHODS 
 
5.1 PCR Mutagenesis 
The human α-galactosidase A gene (GLA, Accession code: NM_000169.2) was 
cloned into a commercial pIB/V5-His-TOPO cloning vector (Invitrogen Life Sciences 
Inc., Carsbad CA, USA).  The pIB/V5-His-TOPO-α-GAL construct encodes the 429 
amino acid residue αGalactosidase A protein, including its 31 amino acid signal 
sequence, and a 6xHis tag at the C-terminus of the enzyme.  The construct also contains 
ampicillin and blasticidin antibiotic resistance genes (figure 2).  Point mutations in GLA 
were introduced to convert α-GAL E203 to S and L206 to A (α-GALSA).  α-GALSA 
mutations were made using Finnzyme’s Phusion Site-Directed Mutagenesis kit 
(Finnzyme, USA) and mutagenesis primers designed as described in the Finnzyme 
protocol (appendix A).  Primers were purchased from Integrated DNA Technologies Inc. 
(1710 Commercial Park, Coralville IA, USA).  Forward primer: 5-/5PO4/G TAC TCC 
TGT TCG TGG CCT GCT TAT ATG TGG CCC-3, and reverse primer: 5-/5PO4/CAC 
AAT GCT TCT GCC AGT CCT ATT CAG GGC-3were used to introduce the 
E203S/L206A mutations into GLA (mutated nucleotides are shown in bold).  Matt 
Metcalf used PCR mutagenesis to introduce point mutations into NAGA generating the α-
NAGAL
EL
 mutant; Forward PCR primer: 5'-/5PO4/CGG CCT CCC CCC AAG GGT 
GAA CTA-3', and reverse PCR primer: 5'-/5PO4/CC TTC ATA GAG TGG CCA CTC 
GCA GGA GAA-3'.   
 
  
23 
 
5.2 Ligation, Transformation, and Sequencing 
The PCR mutagenesis product was ligated and transformed via the heat shock 
method into NEB E. coli competent cells grown on LB ampicillin (100 g/ml) plates.    
Ampicillin resistant colonies were re-streaked, and subsequently inoculated into 50 ml 
LB Amp media (100 g/ml) for DNA amplification.  PIB/V5-His-TOPO-α-GALSA 
mutant plasmid was isolated and the presence of the α-GALSA mutation confirmed via 
sequencing data obtained from Genewiz sequencing services (Genewiz Inc., USA).  
 
5.3 Transfection 
The pIB-V5-His-TOPO-α-GALSA stable cell line construct was transfected into 
Invitrogen High-Five insect cells by adding 1.8 µg of DNA to 36.4 μl of Cellfectin 
reagent (Invitrogen, USA), along with 1.8 ml Hyclone-SFX serum-free media (Thermo 
Fisher Scientific Inc.).  The mixture was incubated for 15 min, and then added it to a T-
25 flask seeded with 3.6 x 10
6
 cells grown with Hyclone-SFX media.   Cells were rocked 
for 6 hours in the presence of the transfection mixture, before 5 ml of fresh SFX media 
was added.  Cells were allowed to reach confluency over 2 days.  Transfections were 
subsequently passaged in SFX media containing blasticidin at a concentration of 100 
μg/ml for two weeks facilitating selection, after which cells were passaged only with SFX 
media.  Protein expression was assayed via western blotting using polyclonal anti-
hexahistidine IgG (Qiagen Inc., USA), and polyclonal anti-α-Galactosidase IgG (Genetel 
Laboratories LLC, USA) primary antibodies.  Blots were developed using 1-Step
TM
 
NBT/BCIP (Thermo Fisher Scientific Inc., USA) after treatment with the appropriate AP 
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conjugated secondary antibody, anti-mouse IgG (Sigma-Aldrich Inc., USA), or anti-
chicken IgY (Genetel Labs LLC) respectively.   
 
5.4 Large Scale Expression and Purification of α-GALSA 
Large scale (8, 1L cultures) stable cell line suspension cultures of the α-GALSA 
mutant cell line were grown at 37C, to a density of ~5-6 x 106 cells/ml for approximately 
3 days.  Supernatant was collected via centrifugation, and NaN3 added to a final 
concentration of 0.01% to prevent bacterial growth.  Supernatant was concentrated and 
buffer exchanged with Ni Wash Buffer (20 mM NaH2PO4, 0.5 M NaCl, 20 mM 
Imidazole, pH 7.5) using a Prep/Scale tangential flow filtration cartridge (Millipore) with 
a 10 kDa MWC.  Retentate was loaded onto a prepacked 5 ml Ni Sepharose 6 Fast Flow 
column (GE Healthcare) equilibrated with binding buffer at a flow rate of 2 ml/min using 
a Bio-Rad Biologic Duo-Flow FPLC (Bio-Rad Laboratories Inc., USA).  Eluted α-
GAL
SA
 was monitored using SDS-PAGE, and pure fractions were pooled and 
concentrated using Sartorius Vivaspin concentrators with a MWC of 10 kDa, and stored 
in 10 mM NaH2PO4. 
Any remaining impure fractions eluted from this Ni affinity column purification, 
along with the flow-through supernatant, were pooled and subjected to a second Ni 
affinity purification using an identical protocol as the one applied to the first Ni 
purification.  Again, fractions were monitored using SDS-PAGE, pure fractions were 
pooled and concentrated using Sartorius Vivaspin concentrators with a MWC of 10 kDa, 
and stored in 10 mM NaH2PO4. 
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Any remaining impure fractions from this second Ni purification were dialyzed 
with anion (Q) Wash Buffer (20 mM Bis-TRIS, pH 7.5) using a dialysis membrane with 
a MWC of 10 kDa .  Dialyzed fractions were loaded onto a 5.0ml UNO
TM
 Q anion 
exchange column (Bio-Rad, USA) at a flow rate of 1ml/min.   Protein was eluted using Q 
Elution Buffer (20 mM Bis-TRIS, 500 mM NaCl, pH 7.5) over a volume of 350 ml.  
Eluted α-GALSA protein was monitored using SDS-PAGE, and pure protein was pooled 
and concentrated using Sartorius Stedim Biotech Vivaspin concentrators with a MWC of 
10 kDa, and stored in 10 mM NaH2PO4 at pH 6.5.  Pure α-GAL
SA
 protein from the two 
Ni and one Q purification were subsequently pooled and further concentrated to ~7 
mg/ml.  
 
5.5 Michaelis Menten Kinetics 
In all experiments the enzymatic hydrolysis of either synthetic substrates para-
nitrophenyl-α-Galactose (pNP-α-Gal) (Toronto Research Chemicals Inc., Canada) or 
para-nitrophenyl-2-acetamido-2-deoxy-α-D-galactopyranoside (pNP-α-GalNAc) 
(Toronto Research Chemicals Inc., Canada) was monitored at an absorbance of 400 nm at 
37º C.  An extinction coefficient of 18.1 mM
-1
 cm
-1
 was used.  The amount of para-
nitrophenolate cleaved by the enzyme of interest with respect to time at varying substrate 
concentrations was used as a measure of the rate of enzyme activity.  The amount of 
product cleaved at each substrate concentration was plotted against time yielding initial 
velocities (V0) for each substrate concentration.  Vmax and Km values were calculated 
using weighted non-linear least squares regression curve fittings of initial velocity as a 
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function of substrate concentration according to the Michaelis-Menten equation 
(Equation 2) using KaleidaGraph.   
V0 = (Vmax [S])/(Km + [S])        (2) 
 
To measure rates, 140 uL of either pNP-α-Gal or pNP-α-GalNAc at varying 
substrate concentrations ([pNP-α-Gal]: 0.047 mM – 50.0 mM; [pNP-α-GalNAc]: 0.047 
mM – 50.0 mM) were incubated with 10 uL of enzyme ([WT-α-GAL]: ~0.025 mg/ml, [α-
GAL
SA]: ~0.1 mg/ml, [α-NAGALEL]: ~0.05 mg/ml, [WT α-NAGAL]: ~0.025 mg/ml) at 
37º C to a final volume of 150 uL.  (For a blank measurement a 10 μL aliquot of the 
reaction mixture was quenched in 290 μL of borate buffer (200 mM Na3BO3, pH 9.8) 
immediately after mixing enzyme and substrate.)  10 uL aliquots were subsequently 
quenched in 290 μL borate buffer every min constituting experimental time points.  All 
experiments were performed using clear flat bottom 96 well plates (Fisher).  Absorbance 
at 400 nm was measured using a Molecular Devices SpectraMax 5 plate reader and data 
was collected using Soft Max Pro.  All stock pNP-α-GalNAc and pNP-α-Gal solutions 
were dissolved in citrate buffer (100 mM Citric Acid, 100 mM NaH2PO4, pH 4.5), and all 
enzyme solutions diluted in 100 mM Citric Acid, 100 mM NaH2PO4, 0.1% BSA, pH 4.5.  
All kinetic experiments were preformed in triplicate each of by two separate 
experimenters. 
 
5.6 Crystallography 
Crystals were grown using the hanging drop vapor diffusion method and 
macroseeding techniques were employed to increase the size of crystals.  Crystals grown 
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with P212121 space group symmetry grew from a crystallization solution that contained a 
reservoir of 8.0% Polyethylene Glycol 8000 (PEG 8k), 22 mM Mg(OAc)2, and 100 mM 
NaCacodylate pH 6.5.  Drops were set up using a 1:1 mixture of reservoir solution and 
stock α-GALSA protein solution (7.0 mg/ml) in 10 mM NaH2PO4, which yielded poor 
diffraction quality crystals.   These crystals were then crushed and used to seed a pre-
equilibrated 1:1 mixture of reservoir solution to stock protein solution and incubated at 
20º C for about 2 weeks.  A number of these crystals were soaked in an α-galactose 
solution (8.0% PEG 8k, 22 mM Mg(OAc)2, 100 mM NaCacodylate pH 6.5, 200 mM 
galactose), prior to harvesting with 8.0% PEG 8k, 22 mM Mg(OAc)2, 100 mM 
NaCacodylate pH 6.5, and 20% Glycerol before the crystals were then flash cooled in 
liquid nitrogen.  A number of small crystals were also harvested into buffer containing 
8.0% PEG 8k, 22 mM Mg(OAc)2, 100 mM NaCacodylate pH 6.5, and 20% glycerol 
before being flash cooled in liquid nitrogen.   
Crystals grown in the C2221 space group were grown using the hanging drop 
vapor diffusion method.  Crystals were grown using a reservoir solution of 12.0% PEG 
8k, 22 mM Mg(OAc)2, and 100 mM NaCacodylate pH 6.5.  Drops were set up using a 
1:1 mixture of reservoir solution to stock α-GALSA protein solution in 10mM NaH2PO4, 
pH 6.5.  Crystal were soaked in either an α-GalNAc, or α-Gal solution (12.0% PEG 8k, 
22 mM Mg(OAc)2, 100 mM NaCacodylate pH 6.5, 200 mM α-GalNAc or 200 mM α-
Gal) prior to harvesting with 15.0% PEG 8k, 22 mM Mg(OAc)2, 100 mM Na Cacodylate 
pH 6.5, and 20% glycerol.  Crystals were subsequently flash cooled with liquid nitrogen.   
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5.7 X-ray Data Collection and Refinement 
Several crystals were screened in house using a Rigaku MSC RU-H3R X-ray 
generator.  Crystals were screened using an exposure time of 5 min to 1 hour under a 
stream of gaseous liquid nitrogen at 100° K, and data detected using a RAxis IV++ 
detector.  Promising crystals were transported to the Brookhaven National Laboratory 
Synchrotron Light Source X6A beamline and the Argonne National Laboratory’s 
NECAT 24-ID-C beamline, where X-ray diffraction data was collected under a stream of 
gaseous nitrogen at 100º K.  Diffraction images were scaled and integrated using 
HKL2000
21
.  The structures were phased by molecular replacement in AmoRe
24
, or by 
Fourier synthesis with human α-GAL mutant D170A (PDB: 3HG3)21.  Atomic model 
building was preformed with the program O
25
, and REFMAC5
24
 was used for refinement.  
Ramachandran plots were computed using PROCHECK
26
, and coordinates were 
superimposed using LSQMAN
27
.  
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CHAPTER 6 
 
FIGURES 
Figure 1:  Structure of Human α-GAL and α-NAGAL.  (Above) Structure of WT 
human α-GAL (green) at 2.3 Å resolution (3HG2)19 superimposed on WT human α-
NAGAL (blue) at 1.9 Å resolution (3H55)
16
 (glycosylation omitted).  The homodimeric 
glycoproteins are homologous. Although sharing only 46% amino acid sequence identity, 
similarity between their secondary structure is extensive
16,19
.  Notice that both enzymes 
contain an N-terminal (β/α)8 barrel harboring the catalytic active site, and a C-terminal β 
sandwich domain composed of eight antiparallel β strands16,19.  (Below)  Blown up view 
of the N-terminal (β/α)8 barrel.  Both enzymes contain a 13 residue active site. 11 of 13 
active site residues are conserved between the two glycoproteins.  Shown in sticks, the 
two non-conserved active site residues E203/L206 (α-GAL), and S188/A191 (α-
NAGAL). The normal WT α-GAL ligand (α-galactose) is shown within the active site in 
yellow.  Images were generated using PyMOL molecular viewer (v1.1, DeLano 
Scientific LLC). 
  
30 
 
 
Figure 2: PCR Mutagenesis Gel.  PCR mutagenesis products were subjected to 0.75% 
agarose gel electrophoresis (stained with EtBr).  Lanes 1 and 9, “U”= Undigested super-
coil, pIB/V5-His-TOPO-α-GAL (control); Lanes 2 and 10, “S”= Single digest, pIB/V5-
His-TOPO-α-GAL (linearized by HindIII restriction enzyme digestion) (control); Lanes 
3-8 and 11-16, PCR mutagenesis products shown at a gradient of annealing temperatures, 
from 62.0° to 70.0° C respectively.  PCR mutagenesis was performed in duplicate 
experiments, using two identical pIB/V5-His-TOPO-α-GAL template constructs.   
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Figure 3: Restriction Digest Gel. The gel shows DNA from E. coli. transformed with 
the α-GALSA construct.  DNA was digested with restriction enzyme, and run on a 0.75% 
agarose gel (stained with EtBr).  Each sample was run undigested (-/-), single-digested 
(+/-), and double-digested  (+/+).  Each well is shown loaded with ~12.0 ng of DNA.  
(Respectively) Lane 1, MW marker (kb); Lanes 2-4, mutant colony 1 uncut, single-digest, 
double-digest; Lanes 5-7, mutant colony 2 uncut, single-digest, double-digest; Lanes 8-
10, mutant colony 3 uncut, single-digest, double-digest; Lanes 11-13, mutant colony 4 
uncut, single-digest, double-digest; Lanes 14-16, mutant colony 5 uncut, single-digest, 
double-digest; Lanes 17-19, mutant plasmid colony 6 uncut, single-digest, double-digest. 
 
 
  
32 
 
 
Figure 4: DNA Sequence Chromatogram of α-GALSA.  The α-GALSA DNA sequence 
chromatogram was assembled with ChromasPro version 1.41 using sequencing data 
obtained from GENEWIZ DNA Sequencing Services.  Codons containing the E203S, 
and L206A mutations are highlighted in dark green, and mutant amino acids in the 
sequence translation are colored blue.  The WT α-GAL DNA sequence is shown aligned 
with α-GALSA.  Mismatched bases between the two sequences show the mutations 
introduced via PCR mutagenesis.  
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Figure 5: Map of pIB-V5-His-TOPO-α-GAL (4.85 kb).  The construct contains GLA 
(Accession code: NM_000169.2), encoding the 429 amino acid α-GAL glycoprotein, and 
its 31 amino acid signal sequence (~1.2 kb).  A 6xHIS tag is linked to the C-terminus of 
the enzyme.  Expression is regulated via the constitutive OpIE-2 promoter.  Blasticidin 
and ampicillin antibiotic resistance genes are present to facilitate eukaryotic and bacterial 
selection, respectively.   
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Figure 6: α-GALSA Stable Cell Line.  (A) A 300 mL suspension culture of the α-GALSA 
stable insect cell line, at 27C.  (B) An adherent culture of the α-GALSA stable insect cell 
line, at 27C.   
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Figure 7: Western Blots of α-GALSA.  Western blots were probed with either 
monoclonal anti-α-GAL, or polyclonal anti-hexahistidine.   Western blots were treated 
with the appropriate alkaline phosphatase conjugated secondary antibody (anti-chicken, 
or anti-mouse) and developed with NBT/BCIP substrate.  (Both western blots): Lane 1; 
N215S α-GAL mutant supernatant from High-5 insect cells (positive control); lane 2, 
Sf21 insect cell supernatant (negative control); lane 3, α-GALSA supernatant from Sf21 
insect cells; lane 4, α-GALSA supernatant from High-5 insect cells.  α-GALSA expressed 
at detectable levels in Tn-5 insect cells.   
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Figure 8: Purification Overview.  Flow chart summarizing the purification process used 
to generate pure α-GALSA protein, at ~7 mg/mL.   
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Figure 9: Tangential Flow Setup.  (Above): Depiction of the tangential flow (TF) 
apparatus.  Tangential flow filtration is used to concentrate and buffer exchange tissue 
culture supernatant.  Supernatant travels to the pump, then to the Millipore cartridge 
(MWC 10 kDa), and back to its reservoir/retentate container (arrows).  Supernatant that 
passes through the cartridge membrane is pumped into the waste container.  (Cartoon): 
Simplified representation of the tangential flow process.  A large volume of supernatant 
is pumped through a filter cartridge until ~1 liter of retentate remains.  The retentate is 
diluted and subjected to further TF concentration.  The filtration continues until the 
retentate is clarified. 
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Figure 10: Ni purification # 1.  ~ 1 liter of concentrated α-GALSA retentate was loaded 
onto a prepacked, 5 ml Ni Sepharose column.  A 25ml wash step (Ni Wash Buffer) 
preceded a 300 ml elution gradient of 0-70% (using Ni Elution Buffer).  The UV 280nm 
absorbance chromatogram is shown in blue.  The elution gradient is shown in black.  
Conductivity is shown in red.  The UV 280 nm absorbance peak corresponding to eluted 
α-GALSA fractions is circled in purple.  Fractions were collected every 2ml, and α-GALSA 
was monitored via SDS-PAGE, stained with Coomassie Brilliant Blue.  (SDS-Gels): First 
lane, MW marker; Lane L, load; lane F, flow-through; all remaining lanes, eluted 
fractions (as labeled).  Eluted α-GALSA appears between the 56 kDa and 43 kDa ladder 
marker, appearing most prevalent between fractions 63 and 127 (purple). 
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Figure 11: Ni purification # 2.  Impure fractions (and the flow-through) from the first 
Ni affinity chromatography purification were subjected to a second Ni purification.  A 25 
ml wash step (Ni Wash Buffer) preceded a 300 ml elution gradient of 0-70% (Ni Elution 
Buffer).  The 280 nm absorbance chromatogram is shown in blue.  The elution gradient is 
shown in black.  Conductivity is shown in red.  The 280 nm absorbance peak 
corresponding to eluted α-GALSA is circled in purple.  Fractions were collected every 2 
ml.  α-GALSA was monitored via SDS-PAGE, stained with Coomassie Brilliant Blue.  
(SDS-Gels): First lane, MW marker; Lane L, load; lane F, flow-through; all remaining 
lanes, eluted fractions (as labeled).  Eluted α-GALSA appears between the 56 kDa and 43 
kDa ladder marker, appearing most prevalent between fractions 70-118 (purple).  
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Figure 12: Anion Exchange Chromatography Purification.  Further purification of 
some fractions proceeded by anion (Q) exchange chromatography.  Impure α-GALSA was 
dialyzed (20 mM Bis-Tris, pH 7.5) overnight, and loaded onto a 1 ml UNO™ Q anion 
exchange column.   An elution gradient of 0-100% (20 mM Bis-Tris, 1 M NaCl, pH 7.5) 
over a volume of 350 ml was used.  The UV 280 nm absorbance chromatogram is shown 
in blue. The elution gradient is shown in black.  Conductivity is shown in red.   The 280 
nm absorbance peak corresponding to eluted α-GALSA is circled in purple.  Fractions 
were collected every 2 ml, and α-GALSA was monitored with SDS-PAGE, stained with 
Coomassie Brilliant Blue. (SDS Gels): First lane, MW marker; Lane L, load; lane F, 
flow-through; all remaining lanes, eluted fractions (as labeled).  Eluted α-GALSA appears 
between the 56 kDa and 43 kDa ladder marker, appearing most prevalent between 
fractions 60-137 (purple). 
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Figure 13: α-GALSA and α-NAGALEL Biochemistry.  (SDS gel): From left to right, 
purified α-GAL, α-GALSA, α-NAGAL, and α-NAGALEL, stained with Coomassie 
Brilliant Blue.  Both α-GAL and α-GALSA (3 glycosylation sites) electrophorese to about 
50 kDa, while α-NAGAL and α-NAGALEL both electrophorese to about 52 kDa (5 
glycosylation sites).  The SDS gel shows that all four proteins are pure, and are at 
approximately equal concentrations.  (Western Blot): From left to right, α-GAL, α-
GAL
SA, α-NAGAL, and α-NAGALEL.  The two western blots were probed with either 
monoclonal anti-α-GAL IgG antibody, or polyclonal anti-α-NAGAL IgG antibody.  Both 
blots were treated with the appropriate alkaline phosphatase conjugated secondary 
antibody and developed with NBT/BCIP substrate.  The data show that each mutant 
protein maintains the antigenicity profile of its corresponding WT parent enzyme.  The 
data also show that cross-reactivity between the mutants or their parent enzymes does not 
occur.   
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Figure 14: Optimal pH and Buffer for α-GALSA.  A plot of α-GALSA activity against 
the synthetic substrate pNP-α-GalNAc, measured between pH 3 to pH 9.2, in either 
citrate or phosphate buffer.  The data show that α-GALSA activity is highest at pH 4.5, in 
citrate buffer.  The assay was conducted using clear flat bottom 96-well sterile plates, and 
400 nm absorbance measurements were taken using a Molecular Devices SpectraMax 
M5 automated plate reader. 
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Figure 15: α-GALSA Specific-Activity.  α-GALSA, α-GAL, and α-NAGAL were 
subjected to specific-activity assays.  The three enzymes were assayed against both pNP-
α-Gal, and pNP-α-GalNAc.  The data show that α-GALSA has higher activity against the 
pNP-α-GalNAc substrate, but that the enzyme is less active than α-NAGAL.  Activity 
was normalized to protein concentration. One Unit releases 1.0 Mole of pNP from pNP-
α-Gal or pNP-α-GalNAc per min, at pH 4.5.     
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4 Figure 16: Michaelis-Menten Kinetic Data.  Michaelis-Menten Kinetic data taken on α-GAL, α-GAL
SA, α-NAGAL, 
and α-NAGALEL by measuring the amount of pNP cleaved from pNP-α-GAL or pNP-α-GalNAc over time , at varying 
concentrations.   
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Figure 17: α-GALSA Crystals.  (Image A, B, C): α-GALSA crystals grown using a 
reservoir solution of 8% PEG 8 k, 22 mM Mg(OAc)2, 100 mM Sodium Cacodylate, pH 
6.5.  Crystals from image A were crushed, and used to seed and nucleate the crystals 
shown in images B and C (P212121 space group symmetry). The crystal in image C 
yielded a 3.2 Å dataset.  (Images D, E, F, G): α-GALSA crystals grown using a reservoir 
solution of 12% PEG 8k, etc,. (C2221 space group symmetry).  Image D shows a large 
crystal demonstrating layered growth with fraying (poor diffraction quality).  Crystals of 
higher diffraction quality are shown in images E, F, and G.  These crystals were ligand-
soaked with a 200 mM α-GalNAc, or 200 mM α-Gal solution prior to cryo-preservation.  
The highest resolution dataset diffracted to 2.1 Å.   
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Figure 18 : α-GALSA Diffraction Images. (A): Five min exposure of the crystal 
depicted in figure 1.15 (B), using a Rigaku MSC RUH3R X-ray generator (in house), 
digitally detected using a Raxis IV++ detector.  The crystal diffracts to about 3.5 Å, 
demonstrates non-overlapping spot shape, and has low mosaicity.  (B): Diffraction image 
taken at the X6A beamline at BNL Synchrotron Light Source, with an exposure time of 
30 seconds.  The more powerful X6A beamline made data collection on such small 
crystals more feasible than if data were collected in house.   
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Figure 19: Crystal Structures of α-GALSA.  (A, B, and C):  σA-weighted 2Fo-Fc total omit electron density maps of α-GAL
SA
 
calculated using SFCHECK.  Ligands and water are shown with electron density.  (A): α-GALSA with α-GalNAc soaked into the 
active site, contoured at 2.0 σ.  (B): α-GALSA with α-Gal soaked into the active site, contoured at 1.8 σ.Cα-GALSA with glycerol 
  
 
4
8 
soaked into the active site, contoured at 1.0 σ.  (D): α-GALSA superimposed over α-NAGAL by their (β/α)8 barrels, with α-GalNAc 
soaked into the active site. The ligands superimpose with an RMS deviation of 0.38 Å.  (E): α-GALSA superimposed over α-GAL by 
their (β/α)8 barrels, with α-Gal soaked into the active site.  The D170 catalytic nucleophile is in a slightly different orientation in the α-
GAL
SA
 structure.  (F): The four crystallographically independent glycerol-soaked monomers of α-GALSA.  The R227 side chain, and 
the β6-α6 loop containing the catylitic acid/base D231 shift in one of the four monomers (green, arrows).  The glycerol also orients 
itself differently in one of the monomers.   
 
 
 
 
 
 
 
  
49 
 
 
Table 1: α-GALSA Data Collection and Refinement Statistics. 
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Cycling step Temperature Time Number of Cycles 
Initial denaturation 98 °C 30s 1 
Denaturation 98 °C 10s  
Annealing 62-70 °C 30s 30 
Extension 72 °C 140s  
Final extension 72 °C 10mins 1 
 4 °C hold  
 
APPENDIX A 
 
PROTOCOLS 
 
Phusion PCR Mutagenesis Protocol 
 
Primers should be designed to a length of 24 to 30 nt.  The forward primer should 
contain the desired mismatch mutations near the primer center, flanked on both sides by 
10-15 perfectly matched nucleotides.  Percent GC content should remain above 50%, and 
the primer annealing temperatures should fall between 65-72˚ C.  Tm should be calculated 
using the nearest neighbor method.  Both primers should be 5 phosphorylated.   
Sample preparation for PCR mutagenesis 
 
Thermocycling protocol 
 
 
Ligation Protocol for Phusion Site-Directed Mutagenesis Kit 
 
 Take 25 ng of PCR product from the mutagenesis reaction, which usually equals 
1-5 µL.  Adjust volume to 5 µL with H2O.  
Component [Final] 50µL 
H2O add to 50µL 35.5µL 
5x Phusion HF Buffer 1x 10.0µL 
10mM dNTPs 200µM 1.0µL 
Primer E203S L206A Forward 
(new) 
0.5µM 1.0µL 
Primer E203S L206A Reverse 0.5µM 1.0µL 
pIB/V5-His-TOPO-Agal 1 
10pg DNA/50µL reaction @ [pIB/V5-His-TOPO-
Agal 1] = 10.0pg/µL 
1.0µL 
Phusion Hot Start DNA 
Polymerase 
0.02U/µL 0.5µL 
 
 51 
 
 
 Add 5 µL of 2x Quick Ligation Buffer and mix.   
 Add 0.5 µL of Quick T4 DNA Ligase and mix. 
 Centrifuge briefly and incubate at room temperature (25° C) for 5 min. 
 Chill on ice, then transform or store at -20 °C. 
 Do not heat inactivate.  Heat inactivation dramatically reduces transformation 
efficiency.   
 
Transformation Protocol 
 
1) Add 10 µL of the ligation mixture to E.coli cells.   
2) Mix by swirling and store cells on ice for 30 min.   
3) Transfer tubes into a water circulation bath at 42 ° C for 90 seconds.  DO 
NOT SHAKE CELLS! 
4) Add transformed cells to 500 µL Lb medium, and incubate for 45 min.   
5) Transfer 100 µL of transformed confluent cells to LB agar plates containing 
Ampicillin. 
6) Let the plates stand for 15 min and then incubate at 37 °C for 12-16 hours.   
7) Split the plates and repeat incubation.   
8)      Store cells in the cooler with parafilm.   
 
Minipreps 
 
 Please consult Promega SV DNA miniprep kit protocol if interested.   
 
 
Transfection: Generating Stable Insect Cell Lines  
 
1) Seed a T-25 flask with 3.6 x 106 cells, with a viability of 95% or higher (the total 
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volume in the flask must be at least 4 ml, so you may need to add SFX to dilute 
the culture).   
2) Allow the cells to adhere for twenty min. 
3) While the cells are adhering make the transfection mixture (I have found that if 
you add the DNA to 1.8 ml of SFX, and then add the Cellfectin directly to the 
mixture, the liposomes form just fine. However, the manufacturer recommends 
the two mixture protocol described below). 
 
Mixture A                                     Mixture B 
0.9 ml SFX                                     0.9 ml SFX 
 
.0364 ml Cellfectin                     1.8 μg plasmid DNA 
 
      4)   Mix the two mixtures and gently invert the tube 10 times. 
5)   Allow the mixture to incubate at room temperature for 15 min (this allows the  
 liposomes to form). 
      6) Confirm that the cells have adhered to the flask-bottom under the microscope. 
      7) Remove the SFX from the adhered culture and very slowly add the transfection  
 media to the culture (the mixture should barely cover the culture when rocking). 
      8) Place the cultures on a rocker, rocking at approximately 2 full rocks / min. 
      9) Allow the cells to rock for 4 hours. 
     10) Add 4 ml of SFX to the culture and place the cells in an incubator at 37°C. 
     11) 48 hours post-transfection remove the SFX/Transfection media from the cells, and  
 replace with fresh SFX with 100 μg/ml blasticidin (you should see blue spheres  
 around some cells). 
12) Replace the media with new selective media every two days until the culture  
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 becomes confluent (usually a week and a half). 
     13) When the selection appears to have been completed replace the media with 5 ml  
 of SFX and suspend the cells. 
 
SDS-PAGE  
 
1) Obtain approximately a 1 ml sample of cell supernatant (supe) and centrifuge at 
500 x g for 10 min.  Afterwards, remove the supernatant from the pellet and 
transfer into a clean vial.  Avoid disturbing any of the cell pellet at the bottom of 
the tube.   
2) Add 50 µL of supe to 10 µL 6x SDS dye containing 10% 2-mercaptoethanol and  
 boil the samples for 10 min.   
3) Make 500 ml of 1x SDS Buffer and fill up the inside of an SDS-PAGE gel box.   
4) Load each well of a 10% gel with 15 µL of boiled sample-prep, and 5 µL of 
protein ladder into lane 1.   
5) Run the gel at 200 V for 45 min.   
 
Western Blot  
1) Make 1 liter of 1x Transfer Buffer with 20% Methanol. 
2) Cut the paper and Nitrocellulose to the appropriate size and soak them in the 
transfer buffer with the pads.   
3) When the SDS-PAGE is complete, assemble the sandwich manifold.  Place the 
negative (black) side down flat.  Over the black side place the pads, paper, gel, 
nitrocellulose membrane, paper, and second pad into the sandwich in that order.   
4) Roll out any bubbles and run the sandwich at 100 V for 60 min.   
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5) After the run, wash the nitrocellulose membrane 2 x in TBS for 10 min.   
6) Block with BSA (25 mg/ml) in TBS-T for at least one hour.   
7) Wash 2x with TBS and 1x with TBST for 10 min.  
8) Incubate with 1° antibody for 1 hour.  (1:2000 IgG polyclonal anti-α-Gal in 10 ml 
TBS-T with BSA) 
9) Wash 2x with TBS and 1x with TBS-T for 10 min.   
10) Incubate with 2° antibody for 1 hour.  (1:5000 anti-chicken in 10ml TBS-T with 
BSA) 
11) Wash 4x with TBS for 10 min. 
12) Develop with 2-3 ml of NBT/BCIP substrate.   
13) Neutralize AP reaction with water. 

α-GALSA Sample-Prep and Purification Protocol 
    
Ni Wash buffer    Ni Elution Buffer 
              20 mM Sodium Phosphate      20 mM Sodium Phosphate 
               500 mM NaCl       500 mM NaCl 
               20 mM Imidazole, pH 7.5                 250 mM Imidazole, pH 7.5 
 
   
 Grow desired amount of cells in culture (usually around 10L).  When cells reach 
~5 x 10^6cells/ml, centrifuge cells and media at 500 x g for 10 min and collect the 
supernant.  Discard the cell pellet, and centrifuge the supernant at max speed for 
about 1 hour.  Again collect the supernant and discard the pellet.  The supe should 
appear very clear. 
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 Add 1 ml of 0.05% Azide for every liter of supe. 
 Perform prep/scale tangential flow filtration.  When the 10 liters of supe reaches a 
volume of approximately 1 liter, add 4 liters of Ni Wash Buffer, and continue 
concentrating.  Allow the supe to concentrate to a volume of about 300 ml, and 
then raise the volume to approximately 1 liter with Ni wash buffer.  Repeat until 
the supe is almost completely clear, with just a slight hint of yellow.  
 Centrifuge the product of tangential flow (retentate) at maximum speed for 
approximately 1 hour and collect the supernant again.  Tangential flow often 
results in some amount of precipitation.   
 Prepare a pre-packed 5 ml HisTrap FF Ni Sepharose affinity column for Ni 
affinity chromatography by stripping and recharging the column.  Refer to 
HisTrapFF manual for instruction on how to strip and recharge their pre-packed 
columns.   
 Pump the load/retentate (isocratic flow) through the column at 2 ml/min for the 
volume of the given load, and be sure to collect the waste.   
 Now collecting fractions, wash the column with 25ml Ni wash buffer at a rate of 2 
ml/min (isocratic flow).   
 Initiate a linear gradient from 0-70% elution buffer over a volume of 300 ml, at a 
flow rate of 2 ml/min.   
 Raise the elution buffer concentration to 100% for 25 ml, at a flow rate of 2 
ml/min.   
 Wash the column with H20 for 25 ml at a rate of 5 ml/min and store the column in 
20% EtOH.   
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 Assay fractions via SDS-PAGE, pooling clean fractions for concentration.  Set 
impure fractions aside for an additional Ni purification, and then a final Q-column 
anion exchange chromatography purification.   
 
Anion Exchange Chromatography Protocol 
   
Q-Wash Buffer    Q-Elution Buffer 
    20 mM Bis-Tris, pH 7.5       20 mM Bis-Tris 
     1.0 M NaCl, pH 7.5 
1)  Prepare 4 liters of Q-wash buffer for dialysis.   
2) Dialyze impure fractions at 4C with Q-wash buffer.  Replace the buffer      
every 2-3 hours and repeat 3-4 times.   
3)  Equilibrate the 1.3 ml Q-column as described in the in the Bio-Rad UNO Q Ion 
Exchange Chromatography Instruction manual. 
4)  Flow the load through the column at a flow rate of 1 ml/min, collecting the flow-
through.   
5)  Wash the column with 10 mL of Q-wash buffer at a flow rate of 1ml/min, now 
collecting fractions (isocratic flow).   
6)  Establish a linear gradient of 0-100% Q-elution buffer over a volume of 300 ml, 
at a flow rate of 1 ml/min while collecting fractions.   
7)  Wash the column with 10 ml of Q-elution buffer (isocratic flow) at a flow rate of 
1 ml/min, collecting fractions. 
8)  Store the column in 20% EtOH.   
9)  Perform SDS-PAGE on fractions and pool clean fractions for concentration. 
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

Protein Concentration 
 
1) Use Sartorius Biolab Products Vivaspin 6 concentrator with a MWC of 10 kDa.  
Refill the concentrators with pooled fractions until all have flowed through the 
concentrator and are at a volume of ~1 ml. Centrifuge at a max of 4000 x g. 
2)  Buffer exchange with 10 mM Sodium Phosphate buffer pH 6.5, and repeat 3 
times.   
3)    When a final volume of about 500 L is reached, attain 280 nm absorbance 
measurements via spectrophotometer and calculate protein concentration.   

para-Nitrophenol-linked Specific-Activity 
  
Reagents: 
A) 100 mM Citrate and 100 mM Sodium Phosphate Buffer, pH 4.5.  Adjust pH with  
  1 M NaOH or 1 M HCl.   
B) 100 mM Citrate and 100 mM Sodium Phosphate Buffer, pH 4.5 with 0.1% 
Bovine Serum Albumin.  (Enzyme diluent) 
C) 5.0 mM para-Nitrophenol N-acetyl-α-D-galactosaminide (pNP-α-GalNAc) or p-
Nitrophenol α-D-galactopyranoside (pNP-α-Gal).   Prepare with reagent A. 
D) 200 mM Borate Buffer, pH 9.8.  Adjust pH with 1 M NaOH.   
E) Enzyme solution.  Prepare α-NAGAL or α-GAL dilutions in reagent B. 
Procedure: Pipette in L the fallowing reagents into suitable containers: 
       Test  Blank 
Reagent C, (PNP-α-GalNAc or PNP-α-Gal)   10 L  10 L 
        Equilibrate to 37C.  Then add: 
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 Reagent E (Enzyme solution)     5 L  --------- 
       Immediately mix and incubate at 37C for exactly 10 min.  Then add: 
 Reagent D (Borate)     100 L 100 L 
 Reagent E (Enzyme solution)     --------- 5 L 
Mix and transfer to suitable cuvettes.  Record Absorbance 400nm for both test and 
blank using a spectrophotometer.   
Calculations: 
 
 
(1) 
 
      Where: 
0.115 = Total volume (in ml) of assay.   
df = Dilution factor.  
18 = Millimolar extinction coefficient of p-Nitrophenolate at 400 nm 
10 = time (in min) of assay per the Unit Definition.   
0.005 = Volume (in ml) of enzyme used.   
 
Units / mg solid    = 
Units / ml enzyme 
Mg solid / mg enzyme 
Units / mg protein    = 
Units / ml of enzyme 
Mg protein / ml of enzyme 
 
 
Unit Definition:  One Unit will release 1.0 mole of para-Nitrophenol from p-
Nitrophenol-α-D-galactosaminide (pNP-α-GalNAc) or para-Nitrophenol α-D-
galactopyranoside (pNP-α-Gal), per min at pH 4.5, 37C.   
Units / ml Enzyme = 
(Abs 400 nm Test - Abs 400 nm Blank) (V) (df) 
(18) (10) (0.005) 
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APPENDIX B 
 
SEQUENCES 
 
Human α-Galactosidase A sequence 
 
 1   aaacaataac gtcattattt aataagtcat cggtgattgg tccgcccctg aggttaatct 
 
 
61   taaaagccca ggttacccgc ggaaatttat gctgtccggt caccgtgaca atgcagctga 
          M   Q  L  R 
  
121  ggaacccaga actacatctg ggctgcgcgc ttgcgcttcg cttcctggcc ctcgtttcct 
       N  P   E  L  H  L   G  C  A  L   A  L  R    F  L  A   L  V  S  W 
 
181  gggacatccc tggggctaga gcactggaca atggattggc aaggacgcct accatgggct 
       D  I  P   G  A  R   A  L  D  N   G  L  A    R  T  P  T  M  G   W44 
 
241  ggctgcactg ggagcgcttc atgtgcaacc ttgactgcca ggaagagcca gattcctgca 
       L  H   W  E  R  F   M  C  N  L   D  C  Q   E  E  P   D  S  C   I64 
 
301  tcagtgagaa gctcttcatg gagatggcag agctcatggt ctcagaaggc tggaaggatg 
       S  E   K  L  F  M   E  M  A  E   L  M  V   S  E  G   W  K  D   A84 
 
361  caggttatga gtacctctgc attgatgact gttggatggc tccccaaaga gattcagaag 
       G  Y   E  Y  L  C   I  D  D  C   W  M  A   P  Q  R   D  S  E   G104 
 
421  gcagacttca ggcagaccct cagcgctttc ctcatgggat tcgccagcta gctaattatg 
       R  L   Q  A  D  P   Q  R  F  P   H  G  I   R  Q  L   A  N  Y   V124 
 
481  ttcacagcaa aggactgaag ctagggattt atgcagatgt tggaaataaa acctgcgcag 
       H  S   K  G  L  K   L  G  I  Y   A  D  V   G  N  K   T  C  A   G144 
 
541  gcttccctgg gagttttgga tactacgaca ttgatgccca gacctttgct gactggggag 
       F  P   G  S  F  G   Y  Y  D  I   D  A  Q   T  F  A   D  W  G   V164 
 
601  tagatctgct aaaatttgat ggttgttact gtgacagttt ggaaaatttg gcagatggtt 
       D  L   L  K  F  D   G  C  Y  C   D  S  L   E  N  L   A  D  G   Y184 
 
661  ataagcacat gtccttggcc ctgaatagga ctggcagaag cattgtgtac tcctgtgagt 
       K  H   M  S  L  A   L  N  R  T   G  R  S   I  V  Y   S  C  E   W204 
 
721  ggcctcttta tatgtggccc tttcaaaagc ccaattatac agaaatccga cagtactgca 
       P  L   Y  M  W  P   F  Q  K  P   N  Y  T   E  I  R   Q  Y  C   N224 
 
781  atcactggcg aaattttgct gacattgatg attcctggaa aagtataaag agtatcttgg 
       H  W   R  N  F  A   D  I  D  D   S  W  K   S  I  K   S  I  L   D244 
 
841  actggacatc ttttaaccag gagagaattg ttgatgttgc tggaccaggg ggttggaatg 
       W  T   S  E  N  Q   E  R  I  V   D  V  A   G  P  G   G  W  N   D264 
 
901  acccagatat gttagtgatt ggcaactttg gcctcagctg gaatcagcaa gtaactcaga 
       P  D   M  L  V  I   G  N  F  G   L  S  W   N  Q  Q   V  T  Q   M284 
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961  tggccctctg ggctatcatg gctgctcctt tattcatgtc taatgacctc cgacacatca 
       A  L   W  A  I  M   A  A  P  L   F  M  S   N  D  L   R  H  I   S304 
 
1021 gccctcaagc caaagctctc cttcaggata aggacgtaat tgccatcaat caggacccct 
       P  Q   A  K  A  L   L  Q  D  K   D  V  I   A  I  N   Q  D  P   L324 
 
1081 tgggcaagca agggtaccag cttagacagg gagacaactt tgaagtgtgg gaacgacctc 
       G  K   Q  G  Y  Q   L  R  Q  G   D  N  F   E  V  W   E  R  P   L344 
 
1141 tctcaggctt agcctgggct gtagctatga taaaccggca ggagattggt ggacctcgct 
       S  G   L  A  W  A   V  A  M  I   N  R  Q   E  I  G   G  P  R   S364 
 
1201 cttataccat cgcagttgct tccctgggta aaggagtggc ctgtaatcct gcctgcttca 
       Y  T   I  A  V  A   S  L  G  K   G  V  A   C  N  P   A  C  F   I384 
 
1261 tcacacagct cctccctgtg aaaaggaagc tagggttcta tgaatggact tcaaggttaa 
       T  Q   L  L  P  V   K  R  K  L   G  F  Y   E  W  T   S  R  L   R404 
 
1321 gaagtcacat aaatcccaca ggcactgttt tgcttcagct agaaaataca atgcagatgt 
       S  H   I  N  P  T   G  T  V  L   L  Q  L   E  N  Y   M  Q  M   S424 
 
1381 cattaaaaga cttactttaa aatgtttatt ttattgcc 
       L  K   D  L  L   STOP 
 
 
Human α-GAL Active Site Amino Acid Residues 
 
     W47, D92, D93, Y134, C142, K168, D170, C172, E203, L206, Y207, R227, D231 
 
Human α-NAGAL Active Site Amino Acid Residues 
 
     W33, D78, D79, Y119, C127, K154, D156, C158, S188, A191, Y192, R213, D217 
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The human lysosomal enzymes α-
galactosidase (α-GAL, E.C. 3.2.1.22) and α-
N-acetylgalactosaminidase (α-NAGAL, E.C. 
3.2.1.49) share 46% amino-acid sequence 
identity and have similar folds. The active 
sites of the two enzymes share 11 of 13 
amino acids, differing only where they 
interact with the 2- position of the 
substrates. Using a rational protein 
engineering approach, we interconverted 
the enzymatic specificity of α-GAL and α-
NAGAL. The engineered α-GAL (which we 
call α-GALSA) retains the antigenicity of α-
GAL but has acquired the enzymatic 
specificity of α-NAGAL. Conversely, the 
engineered α-NAGAL (which we call α-
NAGAL
EL) retains the antigenicity of α-
NAGAL but has acquired the enzymatic 
specificity of the α-GAL enzyme. 
Comparison of the crystal structures of the 
designed enzyme α-GALSA to the wild type 
enzymes shows that active sites of α-GALSA 
and α-NAGAL superimpose well, indicating 
success of the rational design. The designed 
enzymes might be useful as non-
immunogenic alternatives in enzyme 
replacement therapy for treatment of 
lysosomal storage disorders such as Fabry 
disease.  
 
Introduction 
Lysosomal enzymes are responsible for 
the catabolism of metabolic products in the 
cell. Deficiencies in lysosomal enzymes lead 
to lysosomal storage diseases, characterized 
by an accumulation of undegraded substrates 
in the lysosome. In humans, there are at least 
40 different lysosomal storage diseases 
(including, for example, Tay-Sachs, Sandhoff, 
Gaucher, and Fabry diseases), each of which is 
caused by a lack of a specific enzymatic 
activity. Fabry disease is caused by a defect in 
the GLA gene, leading to loss of activity in the 
enzyme alpha-galactosidase (α-GAL, E.C. 
3.2.1.22, also known as α-GAL A)(1). The α-
GAL enzyme cleaves substrates containing 
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terminal α-galactosides, including 
glycoprotein, glycolipids, and 
polysaccharides. Defects in the GLA gene in 
Fabry patients lead to the accumulation of 
unprocessed neutral substrates (primarily 
globotriaosylceramide, Gb3), which then leads 
to the progressive deterioration of multiple 
organ systems and premature death. Fabry 
disease is an X-linked inherited disorder with 
an estimated prevalence of approximately 1 in 
40,000 male births but may be highly 
underdiagnosed (1,2). 
The human gene most closely related to 
the GLA gene is the NAGA gene, encoding the 
enzyme α-N-acetylgalactosaminidase (α-
NAGAL, E.C. 3.2.1.49, also known as NAGA 
and α-GAL B)(3). The two genes are derived 
from a common ancestor (4), encoding 
proteins that share 46% amino-acid sequence 
identity (Fig. 1A); they belong to glycoside 
hydrolase family 27 and clan D (5). The α-
NAGAL enzyme recognizes and cleaves 
substrates containing terminal α-N-
acetylgalactosaminide (α-GalNAc) sugars, and 
(less efficiently) substrates containing terminal 
α-galactosides. Defects in the NAGA gene lead 
to the lysosomal storage disease Schindler 
disease, characterized by the accumulation of 
glycolipids and glycopeptides, resulting in a 
wide range of symptoms, including 
neurological, skin, and cardiac anomalies (3).  
The only approved therapy for the 
treatment of Fabry disease is enzyme 
replacement therapy, where patients are 
injected with recombinant enzyme purified 
from mammalian cell expression systems 
(6,7). One problem with this treatment is that 
up to 88% of patients develop IgG antibodies 
against the injected recombinant enzyme (6,8). 
In patients who make no functional α-GAL 
enzyme, the recombinant α-GAL used in 
enzyme replacement therapy can be treated as 
a foreign antigen. Since the GLA gene is 
located on the X-chromosome, hemizygous 
males who inherit a non-functional copy of the 
gene have no second copy to establish 
immunotolerance.  
Previously, we determined the three-
dimensional crystallographic structures of the 
human α-GAL and α-NAGAL enzymes 
(9,10). As expected for two structures that 
share 46% sequence identity, the overall folds 
of the two enzymes are similar (Fig. 1B & C). 
Each enzyme is a dimer where each monomer 
contains an N-terminal (β/α)8 barrel with the 
active site and a C-terminal antiparallel β 
domain. The monomers of the two enzymes 
superimpose with an RMS deviation of 0.90Å 
for 378 alpha carbons. The active sites of the 
two structures are highly similar, as 11 of the 
13 active site residues are conserved. The only 
differences in the active sites of the two 
structures correspond to where the substrates 
are different: in α-GAL, the residues near the 
2-OH on the substrate include larger glutamate 
and leucine, whereas in α-NAGAL, the larger 
2-N-acetyl on the substrate interacts with the 
smaller serine and alanine residues on the 
enzyme (Fig. 1B & C). As we and others have 
noted, in glycoside hydrolase family 27, the 
two residues primarily responsible for 
recognition of the 2 position of the ligand are 
both located on the same loop in the structure, 
the β5-α5 loop in the (β/α)8 barrel domain (9-
13).  
The similarities between the active sites of 
the enzymes in the family and the proximity of 
the two residues responsible for the 
recognition of the 2 position of the ligand led 
us and others to hypothesize that 
interconversion of the enzyme specificities 
would be possible (9,14). We replaced two 
residues in the active site of α-GAL (E203S 
and L206A), leading to a new protein (α-
GAL
SA
) with the enzymatic specificity of an 
α-NAGAL enzyme. Additionally, we replaced 
two residues in the active site of α-NAGAL 
(S188E and A191L), leading to a new protein 
(α-NAGALEL) with the enzymatic specificity 
of an α-GAL enzyme. In this report, we show 
that the designed enzymes maintain the 
antigenicity of the original protein, but have 
the specificity of the other enzyme. X-ray 
crystallographic studies of the α-GALSA 
protein provide a structural basis for ligand 
specificity in the family of proteins. 
 
Experimental Procedures 
Molecular biology: Human α-GAL and 
human α-NAGAL were expressed in stably 
transfected Trichoplusia ni (Tn5) insect cells 
as described (10,15). The α-GALSA variant 
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was generated from the wild type α-GAL 
construct using PCR-based site-directed 
mutagenesis (forward primer 5’-G TAC TCC 
TGT TCG TGG CCT GCT TAT ATG TGG-
3’ [substitutions in bold] and reverse primer 
5’-CAC AAT GCT TCT GCC AGT CCT 
ATT CAG GGC-3’), ligated, transformed into 
bacteria, and confirmed by sequencing. The α-
NAGAL
EL
 variant was derived from the wild 
type α-NAGAL construct by PCR (forward 
primer 5’-CGG CCT CCC CCC AAG GGT 
GAA CTA-3’ and reverse primer 5’-CC TTC 
ATA GAG TGG CCA CTC GCA GGA 
GAA-3’), ligated, transformed into bacteria, 
and sequenced.  
Cell transfection: Adherent Tn5 cells in 
SFX media were transfected with plasmid 
DNA, and selection for stably transfected cells 
using 100 μg/mL blasticidin (added after 48 
hours and every 48 hours for 10 days). Stable 
adherent cells were re-suspended in SFX 
media for larger scale suspension cultures.  
Protein expression and purification: 1L 
cultures of stable cells secreting α-GALSA and 
α-NAGALEL proteins were grown to 3 x 106 
cells/ml. The supernatant was clarified and 
concentrated by tangential flow filtration 
(Millipore Prep/Scale) and exchanged into 
Ni
2+
 binding buffer (50mM Na3PO4, pH 7.0, 
250mM NaCl, 20mM imidazole, and 0.01% 
NaN3). The filtrate was loaded onto a Ni
2+
-
Sepharose
 
6 Fast Flow column (GE 
Healthcare) and eluted with a gradient of 0-
60% elution buffer (50mM Na3PO4, pH 7.0, 
250mM NaCl, 250mM imidazole, and 0.01% 
NaN3). Eluate fractions were pooled, desalted, 
and concentrated before loading onto a Source 
15Q anion exchange column. Fractions eluted 
by a linear salt gradient were screened by 
activity assays and by western blots. Fractions 
containing pure protein were pooled and 
concentrated to 1.0 mg/mL for storage.  
Kinetic assays: Hydrolysis of the synthetic 
substrates para-nitrophenyl-α-galactose (pNP-
α-Gal) and para-nitrophenyl-α-N-
acetylgalactosamine (pNP-α-GalNAc) 
(Toronto Research Chemicals) at 37°C were 
monitored by absorbance at 400nm using an 
extinction coefficient of 18.1 mM
-1
 cm
-1
. 0.25-
1.2ug of enzyme in 100mM citrate/phosphate 
buffer pH 4.5 was added to 12 substrate 
concentrations (pNP-α-Gal from 0.1 to 50mM, 
and pNP-α-GalNAc from 0.01 to 10mM). 
Each minute for 10 minutes, the sample 
absorbance was measured after adding 
200mM Na3BO3 buffer, pH 9.8. Error bars 
were determined from triplicate measurements 
by two experimenters for each data point. KM, 
Vmax, and kcat and error bars were determined 
from a weighted fit of Michaelis-Menten 
hyperbola in KaleidaGraph. Substrate 
solubility limits prevented saturation in some 
experiments. Substrate specificity ratios for 
each enzyme were defined as (kcat/KM)pNP-α-
GalNAc / (kcat/KM)pNP-α-Gal, indicating the 
preference of an enzyme for galactosaminide 
substrates. 
Crystallization and X-ray data collection: 
Crystals of α-GALSA were grown as described 
for the D170A α-GAL variant (15). Crystals 
were obtained from a 1:1 mixture of reservoir 
solution [12% PEG 8K, 0.1M Na cacodylate 
pH 6.5, and 22mM Mg(CH3COO)2] and 7.0 
mg/mL protein in 10mM Na3PO4, pH 6.5. 
Crystals were transferred stepwise into 
reservoir solution containing 200mM ligand 
(GalNAc or galactose) and then into 
cryoprotectant solution (15% PEG 8K, 0.1M 
Na cacodylate pH 6.5, 22mM Mg(CH3COO)2, 
20% glycerol, and 200mM ligand). Crystals 
were flash cooled in liquid nitrogen and X-ray 
data were collected at 100K at beamline X6A 
at the Brookhaven National Laboratory or at 
the microfocus beamline NECAT 24-ID-C at 
Argonne National Laboratory. X-ray images 
were processed using HKL2000 (16) and 
phased by molecular replacement in AMoRe 
(17) or by Fourier synthesis using human α-
GAL coordinates (PDB: 3HG3) (15). We 
selected the overall resolution limits based 
upon I/σI criteria. Atomic models were built 
using the program O (18), with refinement in 
REFMAC5 (17). Ramachandran plots were 
computed using PROCHECK (19). 
Coordinates were superimposed using 
LSQMAN (20). Figures were made in 
MolScript (21) and POVScript+ (22). 
Coordinates and structure factors are deposited 
in the Protein Data Bank under accession 
codes 3LX9, 3LXA, 3LXB, and 3LXC. 
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Results  
Biochemical Characterization 
We expressed the four enzymes (α-GAL, 
α-GALSA, α-NAGAL, and α-NAGALEL) in 
stably transfected Tn5 insect cells and purified 
protein from the supernatant. SDS-PAGE 
analysis shows that the purified variant 
proteins migrate at the same size as their wild-
type equivalents, approximately 50kDa for α-
GAL and α-GALSA and 52kDa for α-NAGAL 
and α-NAGALEL (Fig 1D). To test the 
antigenicity of the wild type and variant 
proteins, we performed western blots on all 
four proteins using antibodies against human 
α-GAL and human α-NAGAL. α-GAL and α-
GAL
SA
 cross-react only with the anti α-GAL 
antibody, while α-NAGAL and α-NAGALEL 
cross-react only with the anti α-NAGAL 
antibody (Fig 1E), indicating that the variant 
proteins retain their original antigenicity.  
 
Enzymatic Activity 
We tested the four enzymes against two 
synthetic substrates, para-nitrophenyl-α-
galactose (pNP-α-Gal) and para-nitrophenyl-
α-N-acetylgalactosamine (pNP-α-GalNAc). In 
the wild type enzymes, the larger active site of 
α-NAGAL allows it to bind and cleave both 
substrates, although less efficiently against 
pNP-α-Gal. The smaller active site of α-GAL 
allows for efficient catalysis of pNP-α-Gal, 
but no detectable activity on pNP-α-GalNAc 
due to steric clashes between the N-acetyl 
group on the 2-position of the sugar and the 
larger E203 and L206 side chains of α-GAL. 
Table 1 summarizes the enzyme kinetic data. 
The variant enzymes α-GALSA and α-
NAGAL
EL
 show the opposite substrate 
specificity compared to their starting wild type 
enzymes. The α-NAGALEL enzyme shows the 
catalytic properties of wild type α-GAL: it has 
no activity against the pNP-α-GalNAc 
substrate, but shows high activity against pNP-
α-Gal. The α-GALSA enzyme has the catalytic 
properties of wild type α-NAGAL: it has high 
activity against pNP-α-GalNAc and reduced 
activity against pNP-α-Gal.  
Since the enzymes in this family have 
overlapping substrate specificity, we used the 
ratio of the specificity constant kcat/KM for the 
two substrates as a measure of the enzymes’ 
ability to discriminate between the two related 
substrates. The substrate specificity ratios 
(kcat/KM)pNP-α-GalNAc / (kcat/KM)pNP-α-Gal for α-
GAL and α-NAGALEL are zero because those 
enzymes show no activity towards the pNP-
α-GalNAc substrate. The substrate specificity 
ratios for α-NAGAL and α-GALSA are similar: 
57.3 ± 10.3 for α-NAGAL and 42.9 ± 9.0 for 
α-GALSA, showing they have comparable 
ability to distinguish between the two 
substrates. 
Comparison of the enzymatic parameters 
of α-GAL and of α-NAGALEL (the enzyme 
engineered to have α-galactosidase activity) 
shows that the KM values of the two enzymes 
are similar (6.9 and 7.6 mM respectively for 
the pNP-α-Gal substrate). The engineered 
enzyme has a turnover number kcat that is 
approximately 1/3 that of the native α-GAL 
enzyme (13.7 sec
-1
 vs. 37.8 sec
-1
 respectively).  
Comparison of the enzymatic parameters 
of α-NAGAL and of α-GALSA reveals that the 
KM value of the engineered enzyme against the 
pNP-α-GalNAc substrate is 30-fold larger than 
that of the wild type enzyme (21.0 and 0.68 
mM respectively) and 2-fold larger against the 
pNP-α-Gal substrate (49.1 and 27.5 mM 
respectively). The turnover numbers kcat of α-
NAGAL and α-GALSA are similar against the 
pNP-α-GalNAc substrate (15.1 and 21.5 sec-1 
respectively) and differ 9-fold against the 
pNP-α-Gal substrate (10.7 vs. 1.2 sec-1) 
Overall the kinetic parameters show that, 
although the engineered enzymes are not as 
efficient as their wild-type counterparts, they 
have the same ability to discriminate among 
different substrates as their wild-type 
equivalents. In particular, the α-GALSA 
engineered enzyme is somewhat less effective 
at catalyzing the turnover of substrate 
compared to its wild type equivalent, α-
NAGAL.  
 
Crystal structures 
To examine the structural basis for the 
reduced catalytic efficiency of the α-GALSA 
enzyme, we determined four crystal structures 
of α-GALSA in complex with three different 
ligands, N-acetylgalactosamine (GalNAc), 
galactose, and glycerol (Table 2 and Fig. 2A-
C). Superposition of α-GALSA and α-NAGAL 
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by their (β/α)8 barrel domains results in an 
RMS deviation of 0.58 Å for 290 Cα atoms in 
the domain. Remarkably, the superposition of 
the entire (β/α)8 domains shows that the 
GalNAc ligands and the active site residues 
superimpose nearly exactly (Figure 2D). 
Although 54% of the residues differ between 
α-NAGAL and α-GALSA, the ligands 
superimpose with an RMS deviation of 0.38 Å 
for the 15 atoms in the ligand. 
Superposition of the (β/α)8 barrel domains 
of α-GALSA and α-GAL shows that the active 
site residues and ligands superimpose closely, 
except for E203 and L206 in α-GAL, which 
are replaced with S and A in α-GALSA (Figure 
2E). The structure of α-GALSA with galactose 
bound shows a shift in the location of the 
catalytic nucleophile D170 relative to its 
location in other structures in the family. The 
D170 nucleophile shifts into the empty space 
produced by the reduction in size of the side 
chain in the E203S substitution. This shift 
affects the hydrogen bonding of D170 to Y134 
and Y207, and likely contributes to the 
reduced catalytic efficiency of the α-GALSA 
variant protein.  
The crystallographic experiments used the 
cryoprotectant glycerol, which appeared in the 
active site of α-GALSA. We determined two 
structures of glycerol-soaked α-GALSA in 
space groups C2221 and P212121. Because 
each crystal has two monomers of the protein 
in the asymmetric unit, we have four 
crystallographically-independent active site 
complexes with glycerol. One of the four 
glycerol-soaked monomers shows significant 
changes in the active site: the glycerol binds in 
a different orientation, the R227 side chain 
rotamer changes, and the β6-α6 loop 
containing the catalytic acid/base D231 shifts 
as well (Figure 2F). This large rearrangement 
in the active site is unique to α-GALSA among 
the glycosidase family 27 structures and may 
also contribute to the reduced catalytic 
efficiency of α-GALSA.  
 
Discussion 
The active site of human α-GAL is unable 
to accommodate 2-N-acetylated ligands due to 
steric clashes between the protein and the N-
acetyl group on the ligand. Here, we have 
engineered α-GALSA, the first α-GAL enzyme 
capable of binding α-GalNAc ligands. In the 
reciprocal experiment, the engineered α-
NAGAL
EL
 enzyme has lost all of its activity 
against α-GalNAc ligands and has enhanced 
activity against α-galactosides. 
 
Enzyme replacement therapy 
Enzyme replacement therapy can 
successfully treat Fabry disease. However, up 
to 88% of male patients develop an immune 
response to the injected recombinant enzyme, 
including both IgG- and IgE-based reactions 
(6,8,23). The antigenicity of the glycoproteins 
used in enzyme replacement therapy for Fabry 
disease patients might limit the effectiveness 
of the treatment by reducing the amount of 
enzyme effectively delivered to the lysosomes. 
We envision the α-NAGALEL molecule would 
have little immunogenicity in Fabry disease 
patients (who make typical amounts α-
NAGAL glycoprotein and are thus 
immunologically tolerant toward α-NAGAL). 
Consistent with this, heterozygous female 
Fabry disease patients (with one wild-type 
copy of the GLA gene) do not make the 
comparable immune responses as their 
hemizygous male counterparts against injected 
enzyme during enzyme replacement therapy 
(24,25).  
Although patients with the severe form of 
Fabry disease have little or no α-GAL enzyme 
activity, patients with the variant forms of 
Fabry disease can have from 5 to 35% of wild 
type enzyme activity (26,27). This suggests 
that the threshold level of α-GAL enzymatic 
activity necessary to prevent Fabry disease 
symptoms is less than 100% wild type 
activity. Although the enzymatic activity of 
the engineered proteins is lower than their 
wild-type equivalents, in enzyme replacement 
therapy, the reduced immunogenicity of the 
designed proteins might compensate for their 
reduced activity. 
Sakuraba and colleagues have also tested 
this hypothesis by reporting a protein similar 
in design to α-NAGALEL, but expressed in 
Chinese hamster ovary cells, leading to a 
different glycosylation pattern (14). When 
injected in a mouse model of Fabry disease, 
the mammalian-expressed protein led to a 
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reduction in the amount of Gb3 in the tissues 
of the mouse. This further suggests that the 
designed enzyme might act as a useful tool for 
the treatment of Fabry disease. 
 
Properties of the engineered enzymes 
Western blotting with anti α-GAL and anti 
α-NAGAL antibodies shows that the former 
reacts only with α-GAL and α-GALSA, while 
the latter reacts only with α-NAGAL and α-
NAGAL
EL
. The sequence divergence between 
α-GAL and α-NAGAL is sufficient to show no 
immunological cross reactivity. Thus, 
engineering the active sites of α-GAL and α-
NAGAL to have novel substrate specificities 
leads to new enzyme activities without 
altering antigenicity. This approach may be 
useful as a general strategy for protein-based 
therapeutics where reducing immunogenicity 
is an issue, such as Gaucher disease, where 
15% of patients on enzyme replacement 
therapy develop IgG antibodies to the 
recombinant enzyme (28).  
The diverse sequences in glycoside 
hydrolase family 27 (which includes human α-
GAL and α-NAGAL) show high conservation 
of the active site residues, indicating strong 
evolutionary pressure on the active site. One 
modular component of ligand binding in the 
family is the recognition of the 2- position of 
the sugar ring. In this family, a single loop on 
the protein, the β5-α5 loop in the N-terminal 
domain, interacts with the substituent on the 2- 
position of the sugar. The similarity across the 
members of the family allowed us to 
interconvert the ligand recognition through 
substitution of two residues in the loop. The 
modularity of the loop is also seen in the 
structures of other members of the family, 
including the rice and Hypocrea jecorina α-
GAL structures, where one turn of helix in the 
β5-α5 loop is replaced with a shorter loop and 
a longer β5 strand (12,29). In those structures, 
Cys and Trp residues fill the space of the E203 
and L206 residue of α-GAL or the S188 and 
A191 residues in α-NAGAL.  
The newly engineered enzymes α-GALSA 
and α-NAGALEL are not as catalytically 
efficient as their wild-type equivalents. The 
structures of α-GALSA suggest that there is 
considerably more flexibility in the active site 
of the α-GALSA enzyme when compared to α-
NAGAL, the enzyme with an identical active 
site constellation.  
The glycerol-soaked structures of α-
GAL
SA
 provide a structural explanation for the 
reduced catalytic efficiency of the engineered 
enzyme. When the larger E203 and L206 
residues of α-GAL are replaced with smaller S 
and A residues in α-GALSA, the active site has 
more open space in it. This allows the R227 
side chain to move toward the space vacated 
by the shortening of the E203 side chain, and 
the β6-α6 loop containing D231 moves toward 
the space vacated by the shortening of the 
L206 side chain. The crystal structures 
indicate that the active site of α-GALSA is 
more dynamic than the active sites of the wild 
type enzymes α-GAL and α-NAGAL, which 
might explain the reduced catalytic efficiency 
of the designed α-GALSA enzyme. Another 
indication of the higher mobility of the active 
site of α-GALSA appears in the glycerol-
soaked α-GALSA structure, which has higher 
atomic B-factors in the rearranged β6-α6 loop. 
In this report, we describe the first 
instance of bidirectional interconversion of the 
enzymatic activities of two human lysosomal 
enzymes. Rational design of enzymatic 
function is a challenging task and generally 
requires large changes in the active site: for 
example, the classic case of conversion of 
trypsin activity into that of chymotrypsin 
required 11 substitutions in four sites on the 
protein (30). In general, changing substrate 
specificity is easier than changing the reaction 
mechanism of an enzyme (31). The family of 
lysosomal glycosidases might prove to be a 
fruitful target for further enzyme engineering, 
since many glycosidases use a similar 
mechanism with an arrangement of two 
carboxylates located on opposite sides of the 
glycosidic linkage to be cleaved.  
In conclusion, we have shown the viability 
of a rational design approach to engineering 
new functionality into human lysosomal 
enzymes. This approach allows for encoding 
new enzymatic functions into existing protein 
scaffolds. By reusing existing proteins in new 
ways, our approach avoids the 
immunogenicity problems that are frequently 
seen in enzyme replacement therapies. This 
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approach might also be used for a wide range 
of protein-based therapeutics when 
immunogenicity problems exist. 
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Figure Legends 
Figure 1: α-GAL and α-NAGAL structural and biochemical analyses 
A: Sequence alignment of the α-GAL and α-NAGAL proteins. Active site residues are red, and 
identities have yellow backgrounds. The two active site residues that differ are boxed. B and C: 
Ribbon diagrams of α-GAL (green) and α-NAGAL (cyan) with attached carbohydrates. Insets 
show the active sites of α-GAL and α-NAGAL with their catalytic products α-galactose and α-
GalNAc respectively (white). 11 of the 13 active site residues are conserved between the 
enzymes, although the overall sequence identity is 46%. The two residues that differ (E203 and 
L206 in α-GAL; S188 and A191 in α-NAGAL) select for the substituent on the 2- position of the 
ligand. D: The four purified proteins are shown on a Coomassie-stained SDS gel. α-GAL and α-
GAL
SA
 (with 3 N-linked glycosylation sites each) run smaller on the SDS gel than α-NAGAL and 
α-NAGALEL (with five N-linked glycosylation sites each). E: Western Blots of the four proteins, 
detected with polyclonal anti-α-GAL (top) and polyclonal anti-α-NAGAL antibodies (bottom). 
The variant proteins retain the antigenicity of the original proteins. 
 
Figure 2: α-GALSA crystal structures 
A, B, and C: σA-weighted 2Fo-Fc total omit electron density maps of α-GAL
SA
 calculated in 
SFCHECK (17). A: GalNAc-soaked crystal contoured at 2.0σ. B: Galactose-soaked crystal 
contoured at 1.8σ. C: Glycerol-soaked crystal soaked at 1.0σ. Maps have a cover radius drawn 
around ligands and/or waters in the active site. Active site residues are labeled in (A). D: A 
superposition of crystal structures of the active sites of α-GALSA and α-NAGAL, each with α-
GalNAc bound in the active site. When the structures are superimposed by their (β/α)8 barrels, the 
ligands superimpose nearly exactly. E: A superposition of crystal structures of the active sites of 
α-GALSA and α-GAL, each with α-galactose bound in the active site. F: A superposition of the 
four monomers of glycerol-soaked α-GALSA, with glycerol bound in the active site. In one of the 
four structures (green), the glycerol binds in a vertical orientation, and shows differences in R227 
and the loop containing D231 (arrows). 
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Tables 
 
Table 1: Enzymatic parameters 
 
 
 
 
 
Substrate:   pNP-α-Gal pNP-α-GalNAc 
Enzyme KM (mM) kcat (sec
-1
) 
kcat / KM  
(mM
-1
 sec
-1
) KM (mM) kcat (sec
-1
) 
kcat / KM  
(mM
-1
 sec
-1
) 
-GAL 6.88 ± 0.07 37.8 ± 0.2 5.49 ± 0.06 No activity detected * 
-NAGAL
EL
 7.58 ± 0.07 13.7 ± 0.1 1.81 ± 0.02 No activity detected * 
-NAGAL  27.5 ± 4.7 10.7 ± 0.9 0.39 ± 0.07 0.68 ± 0.01 15.1 ± 0.1   22.4 ± 0.1 
-GAL
SA
 49.1 ± 7.2 1.20 ± 0.14 0.024 ± 0.005 21.0 ± 0.8 21.5 ± 0.7     1.03 ± 0.03 
* kcat < 0.01 sec
-1
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Table 2: α-GALSA Data Collection and Refinement Statistics 
Ligand: GalNAc  Galactose Glycerol Glycerol 
  PDB ID: 3LX9 3LXA 3LXB 3LXC 
Data Collection: 
Beamline APS 24-ID-C NSLS X6A NSLS X6A APS 24-ID-C 
Wavelength (Å) 1.07188 0.98010 0.98010 1.07188 
Space group C2221 P212121 P212121 C2221 
Resolution (Å)  
  (last shell) 
50-2.05  
(2.09-2.05) 
50-3.0 
(3.11-3.0) 
50-2.85 
(2.90-2.85) 
50-2.35 
(2.39-2.35) 
Cell parameters 
  a, b, c (Å) 
89.95, 139.49, 
182.58 
59.50, 105.85, 
181.85 
59.57, 106.92, 
181.51 
89.75, 139.77, 
182.45 
No. of observations 481,042 172,299 136,330 193,566 
No. of unique observations  
  (last shell) 
72,009 
(3,354) 
23,638 
(2,309) 
27,897 
(1,334) 
47,535 
(2,335) 
Multiplicity  
  (last shell) 
6.7 
(3.6) 
7.3 
(7.2) 
4.9 
(4.9) 
4.1 
(4.0) 
Completeness (%)  
  (last shell) 
99.4 
(93.3) 
100.0 
(99.9) 
99.3 
(99.9) 
98.6 
(98.7) 
Rsym  
  (last shell)  
0.120 
(0.701) 
0.271 
(0.851) 
0.177 
(0.616) 
0.153 
(0.862) 
I/σI  
  (last shell) 
18.6 
(1.6) 
7.6 
(1.8) 
9.1 
(2.2) 
12.3 
(2.0) 
Refinement: 
Rwork/Rfree , % 17.62/21.82 21.45/24.39 22.50/26.38 18.35/23.68 
No. of atoms 
  Protein 
  Carbohydrate 
  Water 
  Other 
7057 
6241 
257 
559 
0 
6557 
6303 
218 
36 
0 
6657 
6320 
170 
131 
36 
7032 
6241 
227 
552 
12 
Average B, Å
2
 37.5 34.5 32.5 45.3 
Protein Average B, Å
2
 36.3 33.9 31.8 44.4 
Ramachandran Plot: 
  Favored (%) 
  Allowed (%) 
  Generous (%) 
  Forbidden  (%) 
 
91.4 
8.0 
0.3 
0.3 
 
89.5 
9.6 
0.6 
0.3 
 
89.5 
9.6 
0.9 
0.0 
 
89.7 
9.5 
0.7 
0.1 
RMS deviations: 
  Bonds (Å) 
  Angles (°) 
 
0.0053 
1.056 
 
0.0150 
1.502 
 
0.0088 
1.222 
 
0.0081 
1.172 
Rsym=ΣhΣi|Ih,i-<Ih>|/ΣhΣi|Ih,i|, where Ih,i is the i
th
 intensity measurement of reflection h and <Ih> is the 
average intensity of that reflection. 
Rwork , Rfree=Σh|FP-FC|/Σh|FP|, where FC is the calculated and FP is the observed structure factor amplitude 
of reflection h for the working or free set, respectively. 
Ramachandran statistics were calculated in PROCHECK. 
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Figure 1 
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Figure 2 
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